University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2021

Computational Imaging Biomarkers For Precision Medicine:
Characterizing Heterogeneity In Breast Cancer
Rhea Chitalia
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations

Recommended Citation
Chitalia, Rhea, "Computational Imaging Biomarkers For Precision Medicine: Characterizing Heterogeneity
In Breast Cancer" (2021). Publicly Accessible Penn Dissertations. 5571.
https://repository.upenn.edu/edissertations/5571

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/5571
For more information, please contact repository@pobox.upenn.edu.

Computational Imaging Biomarkers For Precision Medicine: Characterizing
Heterogeneity In Breast Cancer
Abstract
In the United States, 1 in 8 women are diagnosed with breast cancer. Breast tumor heterogeneity is wellestablished, with intratumor heterogeneity manifesting spatially and temporally. Increased heterogeneity
is associated with adverse clinical outcomes. Current critical disease treatment decisions are made on
the basis of biomarkers acquired from tissue samples, largely under sampling the heterogeneous disease
burden. In order to drive precision medicine treatment strategies for cancer, personalized biomarkers are
needed to truly characterize intratumor heterogeneity. Medical imaging can provide anon-invasive, whole
tumor sampling of disease burden at the time of diagnosis and allows for longitudinal monitoring of
disease progression. The studies outlined in this thesis introduce analytical tools developed through
computer vision, bioinformatics, and machine learning and use diagnostic and longitudinal clinical
images of breast cancer to develop computational imaging biomarkers characterizing intratumor
heterogeneity. Intrinsic imaging phenotypes of spatial heterogeneity, identified in dynamic contrast
enhanced magnetic resonance imaging (DCE-MRI) images at the time of diagnosis, were identified and
validated, demonstrating improved prognostic value over conventional histopathologic biomarkers when
predicting 10-year recurrence free survival. Intrinsic phenotypes of longitudinal change in spatial
heterogeneity in response to neoadjuvant treatment, identified in DCE-MRI were identified and leveraged
as prognostic and predictive biomarkers, demonstrating augmented prognostic value when added to
conventional histopathologic and personalized molecular biomarkers. To better characterize 4-D spatial
and temporal heterogeneity, illuminated through dynamic positron emission tomography imaging, a novel
4-D segmentation algorithm was developed to identify spatially constrained, functionally discrete
intratumor sub-regions. Quantifying the identified sub-regions through a novel imaging signature
demonstrated the prognostic value of characterizing intratumor heterogeneity when predicting recurrence
free survival, demonstrating prognostic improvement over established histopathologic biomarkers and
conventional kinetic model derived parameters. Collectively, the studies in this thesis demonstrate the
value of leveraging computational imaging biomarkers to characterize intratumor heterogeneity. Such
biomarkers have the potential to be utilized towards precision medicine for cancer care.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Bioengineering

First Advisor
Despina Kontos

Keywords
Computer Vision, Imaging Biomarkers, Informatics, Radiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/5571

COMPUTATIONAL IMAGING BIOMARKERS FOR PRECISION MEDICINE:
CHARACTERIZING HETEROGENEITY IN BREAST CANCER
Rhea Devang Chitalia
A DISSERTATION
in
Bioengineering
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2022

Supervisor of Dissertation

________________________
Despina Kontos
Matthew J. Wilson Associate Professor of Research Radiology II
Graduate Group Chairperson

_________________________
David Mankoff, Matthew J. Wilson Professor of Radiology
Dissertation Committee:
Joel Karp, Professor of Radiologic Physics in Radiology
Michael D. Feldman, Professor of Pathology and Laboratory Medicine

COMPUTATIONAL IMAGING BIOMARKERS FOR PRECISION MEDICINE:
CHARACTERIZING HETEROGENEITY IN BREAST CANCER
COPYRIGHT
2022
Rhea Devang Chitalia

“To my mother, my grandmother, and the other 1 in 8 women diagnosed with breast cancer.”

iii

ACKNOWLEDGMENTS
I am enormously grateful to my advisor, Dr. Despina Kontos, for her support and
guidance during my academic journey. In thanks to her mentorship, I have experienced immense
personal and professional growth and have gained the confidence to become an independent
scientist. Despina, you have always supported my academic and career goals, encouraged my
intellectual curiosity, and during the most difficult research moments, reminded me to not to take
it too seriously. I am confident that having you as a role model will help me be successful in the
years to come.
I would like to thank the members of my thesis committee, Dr. David Mankoff, Dr. Joel
Karp, and Dr. Michael Feldman for their invaluable feedback, guidance, and shared knowledge in
all aspects of my thesis work and their direct mentorship on research projects. In particular, I
would like to thank Dr. Mankoff for his continued excitement for and support of this thesis work,
and for his advice for my career development.
To the past and present members of the Computational Biomarker Imaging Group
(including those that were members of the Computational Breast Imaging Group), thank you. I
am very fortunate and grateful to have you all as mentors, colleagues, and friends over the past
many years. In particular, I would like to thank Michael Hsieh and Dr. Nariman Jahani for their
invaluable assistance in all things image processing and for teaching me how to use the cluster.
Thank you to Dr. Omid Haji Maghsoudi, Dr. Babak Haghighi, and Dr. Jose Marcio Luna for their
friendship and career guidance. I am incredibly grateful to Dr. Aimilia Gastounioti, for her
friendship and mentorship during my time at Penn. Much of this work would not have been
possible without you. Thank you for always making time to discuss research projects, enjoy
conference outings, and take coffee breaks. Thank you to Vivian Belenky for being a wonderful
mentee and for contributing to studies in this thesis. A very special thank you to Lauren Pantalone
for her friendship since day one of me joining CBIG. To my fellow PhD students, Apurva Singh,
iv

Hannah Horng, and Alex Nguyen, my daily life in the lab was made richer through your
friendship, intelligence, and inside jokes. I am grateful to the past and present members of
CBICA who I have consider as mentors, colleagues and friends. In particular, thank you to
Sarthak Pati for his friendship and for always helping me to debug my CaPTk issues.
This work would not be possible without the brilliant minds, both at Penn and afar, that I
have been fortunate to have collaborated with. Thank you to Dr. Jenny Rowland, Dr. Elizabeth
McDonald, and Dr. Austin Pantel for helping me segment tumors in the oldest of breast images.
Thank you to Dr. Artemis Hatzigeorgiou, Marios Miliotis, and Dr. Spyros Tastsoglou at the
University of Thessaly for your expertise in genomics and molecular profiling and for being great
collaborators during a pandemic. Thank you to Dr. Mark Muzi and Dr. Lanell Peterson at the
University of Washington for your invaluable insight into PET imaging. Special thanks to Dr.
Varsha Viswanath for answering all of my PET questions, for designing all kinds of simulation,
and for guiding me through the dissertation processes.
I have been very fortunate to have amazing mentors and teachers throughout my
academic journey. I would like to thank my teachers at East Ridge High School in Clermont,
Florida and my mentors at Duke University, in particular, Dr. Nimmi Ramanujam and Dr. Jenna
Mueller. I am very grateful to Jenna for encouraging me to pursue a PhD and for showing me
what a strong woman in STEM looks like.
I am extremely grateful to my many friends, including those not named here, that have
been instrumental in my success and sanity during my PhD. Special thanks to Jonathan Galarraga
for his support as we went through this final stretch together. Andrei Georgescu, Fabiana
Zappala, Nick Perkons, Catherine Bautista, and Ryan Leiphart have been great friends since we
started this program together; the dinners, game nights, and nights out have been bright spots
during this PhD experience. To Sadhana Ravikumar, your friendship has been a true highlight of
my time at Penn. Thank you for always listening to my experiment ideas and for accompanying
v

me to coffee breaks, Pottruck classes, and pandemic walks. To my roommate since day one,
Divya Jain, thank you for being my family in Philadelphia. There’s nothing like living in a tiny
apartment during a pandemic lockdown to really test a friendship, and I’m proud that ours easily
made it through. I am so grateful to have shared many years with Sadhana and Divya through this
PhD and to have made life-long friendships. To Sruti Pisharody, Minali Nigam, Eshita Singh,
Janice Yoon, Karina Guzman, and Kasey Cockefair, your friendship over the years is something I
cherish the most.
I could not have done this without the love and support of my amazing family. My late
grandfather, Hasmukhrai Meghani, taught me to always live and work with honesty. My
grandmother, Manjula Meghani, has always showered me with pride and love from across an
ocean. To my grandparents, Suresh and Hansa Chitalia, thank you for your boundless love and
generosity. Your unconditional support and faith in everything I pursue has helped me to achieve
this milestone.
Thank you to my sister-in-law, Haritha, for your constant optimism, pride, and guidance
in everything I do. Most importantly, thank you for bringing Zion into my life. To my brother
Nakul, thank you for always keeping me grounded and for being the person I have looked up to
my entire life. I cannot articulate how important you both are to me.
Thank you to my fiancé, Ashwin Kommajesula. Your unfailing support, optimism, and
ability to see the best in everything and everyone is something I learn from every day. The
Megabus rides were worth it.
Lastly, and most importantly, the biggest thank you to my parents, Devang and Ushma
Chitalia. Everything I have ever accomplished is both due to and for you.

vi

ABSTRACT
COMPUTATIONAL IMAGING BIOMARKERS FOR PRECISION MEDICINE:
CHARACTERIZING HETEROGENEITY IN BREAST CANCER
Rhea Devang Chitalia
Despina Kontos

In the United States, 1 in 8 women are diagnosed with breast cancer. Breast tumor
heterogeneity is well-established, with intratumor heterogeneity manifesting spatially and
temporally. Increased heterogeneity is associated with adverse clinical outcomes. Current
critical disease treatment decisions are made on the basis of biomarkers acquired from
tissue samples, largely under sampling the heterogeneous disease burden. In order to
drive precision medicine treatment strategies for cancer, personalized biomarkers are
needed to truly characterize intratumor heterogeneity. Medical imaging can provide a
non-invasive, whole tumor sampling of disease burden at the time of diagnosis and
allows for longitudinal monitoring of disease progression. The studies outlined in this
thesis introduce analytical tools developed through computer vision, bioinformatics, and
machine learning and use diagnostic and longitudinal clinical images of breast cancer to
develop computational imaging biomarkers characterizing intratumor heterogeneity.
Intrinsic imaging phenotypes of spatial heterogeneity, identified in dynamic contrast
enhanced magnetic resonance imaging (DCE-MRI) images at the time of diagnosis, were
identified and validated, demonstrating improved prognostic value over conventional
histopathologic biomarkers when predicting 10-year recurrence free survival. Intrinsic
phenotypes of longitudinal change in spatial heterogeneity in response to neoadjuvant
treatment, identified in DCE-MRI were identified and leveraged as prognostic and
vii

predictive biomarkers, demonstrating augmented prognostic value when added to
conventional histopathologic and personalized molecular biomarkers. To better
characterize 4-D spatial and temporal heterogeneity, illuminated through dynamic
positron emission tomography imaging, a novel 4-D segmentation algorithm was
developed to identify spatially constrained, functionally discrete intratumor sub-regions.
Quantifying the identified sub-regions through a novel imaging signature demonstrated
the prognostic value of characterizing intratumor heterogeneity when predicting
recurrence free survival, demonstrating prognostic improvement over established
histopathologic biomarkers and conventional kinetic model derived parameters.
Collectively, the studies in this thesis demonstrate the value of leveraging computational
imaging biomarkers to characterize intratumor heterogeneity. Such biomarkers have the
potential to be utilized towards precision medicine for cancer care.
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Chapter 1 : Introduction to dissertation
Breast cancer is currently the most common malignancy and second leading cause
of cancer-related death in women, with 1 in 8 women likely to develop breast cancer
during their lifetime1,2. Cancer is a heterogeneous disease, with inter-tumor heterogeneity
manifesting as variations between breast tumors across patients or as multifocal or
multicentric tumors, and intratumor heterogeneity manifesting as variations within a
single tumor3,4. Breast tumor heterogeneity is increasingly recognized as a key prognostic
and predictive factor4-8. Genetic alterations and adaptive changes in response to dynamic,
microenvironment specific stressors can result in sub-clonal populations with distinct
stromal architecture and physiologic behavior8,9. This can continue to evolve throughout
cancer progression and lead to functionally distinct sub-populations8,10. Increased
intratumor heterogeneity is associated with adverse clinical outcomes11,12 and tumor
progression driven by aggressive subpopulations has been shown to be a mechanism for
recurrence and therapy resistance8.
Intratumor heterogeneity can manifest as spatial heterogeneity or temporal
heterogeneity. Spatial heterogeneity can result in differences in blood flow, vessel
permeability, and proliferation across the tumor volume and may be appreciated through
pharmacokinetic dynamic variations. Temporal heterogeneity is due to longitudinal
changes in the tumor that may arise in response to therapy leading to altered biomarker
expression or to the acquired resistance by specific sub-clones during treatment4,13.

1

Medical imaging is currently used during breast cancer screening14,15,
diagnosis16,17, and treatment management18,19. Imaging modalities can allow for the noninvasive, whole tumor assessment of disease burden, including spatial and temporal
heterogeneity, allowing for 4-D visualization8. Functional imaging modalities can yield
parametric images illuminating various physiologic behaviors. In particular, dynamic
contrast enhanced magnetic resonance imaging (DCE-MRI) is highly sensitive for
primary lesion detection with the added ability to assess tumor vasculature17,20. Dynamic
positron emission tomography (PET) imaging can also quantify specific facets of tumor
molecular biology7,19,21 and provide information beyond that of static imaging22,23.
Advances in computer vision and machine learning have allowed for a
transformation in the quantitative assessment of medical images24-27. Computational
image analytic techniques and algorithms have been developed to leverage mineable,
high dimensional information from medical images. The field of “radiomics” has
introduced multi-parametric imaging features extracted with high

throughput

computational analysis from medical imaging data28. Such features, which may not be
appreciable by the human eye, can provide complementary information to routine,
qualitative clinical analysis. Medical imaging offers an opportunity to fully sample
disease burden and characterize the extent of intratumor heterogeneity. Furthermore,
leveraging computational analytic techniques can enable medical images to serve as
novel non-invasive tumor assays.

2

Currently, critical disease treatment decisions for breast cancer patients are
mainly made on the basis of markers typically acquired from core biopsy or surgical
excision, which usually represents a small fraction of the tumor. Histologic assessment of
such tissue samples determine common prognostic markers including tumor size, shape,
grade, and nodal status, while estrogen receptor (ER) status, progesterone receptor (PR)
status, human epidermal growth factor receptor 2 (HER2) status, and proliferative (Ki67)
status

are

typically

determined

via

immunohistochemistry14,29,30.

Additionally,

commercial prognostic molecular profiling tests such as MammaPrint (Agendia) and
Oncotype DX Recurrence Score (Genomic Health) have been developed to measure
mRNA and assess gene expression profiles respectively, in order to predict a tumor’s risk
of recurrence—however, they are expensive and are not always implemented in routine
diagnosis31. Such conventional clinical prognostic biomarkers and prognostic molecular
tests are largely dependent upon biopsy derived tissue, may be limited by spatial
sampling, and therefore, fall short of characterizing a heterogeneous tumor volume.
Furthermore, such biomarkers determined at the time of diagnosis may overlook temporal
shifts due to dynamic breast cancer progression or response to therapy. As such, they may
be inadequate for characterizing 4-D intratumor heterogeneity.
Qualitative descriptors of radiographic images are widely implemented in clinical
settings, with observations of tumor morphology and “hot spots” utilized to classify
malignant lesions8,16,17. Quantitative measurements describing static and kinetic lesion
behavior in dynamic imaging are largely region-averaged prior to quantitative
assessment, which assumes regions are functionally homogenous32. Beyond these clinical
3

uses of medical imaging, numerous radiomics studies have established relationships
between conventional imaging biomarkers and clinically utilized prognostic markers
from histology and genomics, as well as molecular subtypes33. While these studies have
shown high prognostic capabilities, the derived imaging features are generally averaged
over the entire tumor under the assumption that while heterogeneous, tumors are “wellmixed”28,34. Additionally, conventional radiomic features largely disregard 4-D
differences in the tumor by utilizing spatial or temporal information, alone. Higher order
radiomics features also often lack interpretability, thus limiting their clinical utility.
The goal of this work is to develop novel imaging biomarkers that characterize
spatial and temporal 4-D functional tumor heterogeneity towards the development of
personalized prognostic biomarkers and the non-invasive, in vivo characterization of
functionally heterogeneous tumor biology. The first two studies discussed in this work
focus on evaluating 4-D heterogeneity in DCE-MRI by assessing spatial differences
across the tumor volume by combining whole-tumor assessment with dynamic imaging,
as well as assessing the longitudinal, temporal changes in such 4-D heterogeneity. We
then develop a novel method to identify functionally discrete, spatially constrained subregions in tumors and an imaging signature to characterize these sub-regions. We
leverage the improved functional sampling afforded by dynamic PET imaging to evaluate
4-D spatiotemporal heterogeneity as a prognostic biomarker. Lastly, we explore
extending the developed imaging biomarkers to pre-cancerous breast lesions and explore
additional future directions. This work has been described further in the following
chapters:
4

1. Explore spatial heterogeneity in DCE-MRI images of breast tumors at baseline by
identifying imaging phenotypes. This study will utilize conventional radiomic
features and evaluate the prognostic value of imaging phenotypes of tumor
heterogeneity as a complement to conventional histopathologic biomarkers
(Chapter 3).

2. Explore longitudinal changes in spatial heterogeneity in DCE-MRI images of
breast tumors undergoing neoadjuvant chemotherapy through imaging phenotypes
of change in intratumor heterogeneity. This study will evaluate the prognostic
value of such longitudinal change as a complement to conventional
histopathologic biomarkers and personalized molecular signatures (Chapter 4).

3. Develop a computational method to characterize 4-D pharmacokinetic spatial
heterogeneity in dynamic PET imaging. This methodology leverages both spatial
and temporal information and is evaluated using simulated dynamic PET image
phantoms (Chapter 5).

4. Develop imaging features summarizing 4-D spatiotemporal heterogeneity and
evaluate these features as a prognostic biomarker. This study is evaluated in
dynamic PET images of women diagnosed with locally advanced breast cancer
(Chapter 6).

5

5. Explore the feasibility of developing an unsupervised method to summarize 4-D
pharmacokinetic spatial heterogeneity. This study will evaluate the performance
of this methodology on dynamic PET image phantoms simulating tumor
heterogeneity (Chapter 7).

6. Explore extended applications of quantifying lesion heterogeneity and examine
additional future directions of this thesis work (Chapter 8).

6

Chapter 2 : Background
Subsections of this chapter have been adapted from the following:

Chitalia, R.D. and Kontos, D., 2019. Role of texture analysis in breast MRI as a cancer
biomarker: A review. Journal of Magnetic Resonance Imaging, 49(4), pp.927-938.
Liao, G.J., Henze Bancroft, L.C., Strigel, R.M., Chitalia, R.D., Kontos, D., Moy, L.,
Partridge, S.C. and Rahbar, H., 2020. Background parenchymal enhancement on breast
MRI: a comprehensive review. Journal of Magnetic Resonance Imaging, 51(1), pp.43-61.

2.1. Introduction
Breast cancer is a malignancy originating through ductal hyper proliferation leading
to in situ, invasive carcinoma, and potential metastatic disease5. Breast cancer displays
the hallmarks of cancer shared across organ sites, defined as sustained proliferative
signaling, evasion of growth suppressors, resistance of cell death, enablement of
replicative immortality, increased angiogenesis, and invasion and metastasis35. Breast
cancer has been established as a heterogeneous disease, and such heterogeneity can
manifest both between tumors (inter-tumor heterogeneity) as well as within a single
tumor (intratumor heterogeneity).

2.2. Tumor heterogeneity
Inter-tumor heterogeneity in breast cancer has been illuminated through the
variations in seen across breast tumors36, and has resulted in discrete molecular subtypes.
Breast cancer molecular classification has been largely dictated by the presence or
absence of the immunohistochemistry derived expressions of three main receptors:
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor
7

receptor 2+ (Her2). The increased presence of ER and PR suggests an increased
dependency of the tumor on estrogen and progesterone steroids for growth, while Her2
tumors have an overexpression of the ERBB2 oncogene. As such, luminal breast tumors
are positive for ER and PR, or hormone receptor (HR) status positive, Her2 enriched
breast tumors are HER2+, and basal like breast tumors lack HR and HER2 and are
considered to be triple-negative breast cancers (TNBC)37,38. Incidence rates, metastatic
potential, disease progression, and patient outcome can all be stratified along these
molecular subtypes36,38.
Intratumor heterogeneity refers to the differential properties displayed across
cancer cells, within a tumor4. Such properties and traits can be related to tumorigenesis
including angiogenic, invasive, and metastatic potential4. Given the current understanding
of breast tumor formation, intratumor heterogeneity may stem from the branched
evolution of clonal cells, leading to the generation of multiple sub-clonal populations39,40.
These sub-clonal populations may emerge during the malignancy conversion of nonmalignancy cells, due to genetic and epigenetic alterations, or in response to
microenvironment specific stressors as an adaptive response4,6. Intratumor heterogeneity
remains dynamic through tumor progression as tumor properties may change in response
to treatment due to de-novo or acquired resistance. Additionally, the acquired resistance
by aggressive sub-clonal populations may drive recurrence or metastases40. As such,
increased heterogeneity is associated with adverse clinical outcomes, with higher degrees
of intratumor heterogeneity suggesting inferior responses to targeted treatments and
anticancer therapies39,41-45. Various studies have demonstrated this heterogeneity through
8

single cell and whole-genome sequencing, RNA and microRNA sequencing,
histopathology, and imaging modalities8,46-50.
Intratumor heterogeneity can be spatial—resulting in variations in tumor
properties across the volumetric disease burden, or temporal—resulting in variations in
time seen through dynamic or longitudinal changes in tumor properties4-6,39. Spatial
heterogeneity can often be appreciated through differences in tumor blood flow9,
metabolism51, or proliferation52 across the tumor volume. Temporal heterogeneity may
include the dynamic heterogeneity demonstrated by tumors over shorter periods of time
in response to a pharmacokinetic agent, or longitudinal changes in tumor behavior
following natural disease progression or therapy.

2.3. Clinical management of breast cancer
Breast cancer is most commonly detected through screening mammograms or
through a palpable breast mass. Of breast lesions diagnosed in the United States,
approximately 62% are confined to the breast, 31% have spread to regional lymph nodes,
and 6% are metastatic at the time of diagnosis53. Breast cancer is most commonly
diagnosed through histopathologic assessments from fine-needle aspiration, core biopsy,
or surgical excision, and molecular biomarkers evaluated during this assessment often
define treatment paradigms. For non-metastatic breast tumors, the goal of tumor
eradication usually involves surgical resection and removal of axillary lymph nodes. In
addition to this, therapy can include neoadjuvant (prior to surgery) or adjuvant (postsurgery) chemotherapy, radiation, and targeted therapies to prevent metastases or
recurrence. Current conventional targeted therapies are specific to the molecular
9

receptors identified during histopathologic assessment. Endocrine therapy is suggested
for HR+ tumors, such as anti-estrogen or aromatase inhibitory treatment. Antibody
therapy is suggested for HER2+ tumors; Herceptin, a monoclonal antibody specifically
targeted for HER2 receptor was developed to block intracellular signaling pathways,
promote apoptosis, and promote cell proliferation54. A greater understanding of breast
tumor biology has led to the identification of numerous molecular targets and targeted
therapeutics, including inhibitors of growth factor tyrosine kinase, inhibitors of signaling
pathways, and anti-angiogenic strategies55,56.
Medical imaging allows for the non-invasive, whole tumor sampling of disease
burden, with the ability to longitudinally monitor response to treatment16,17. Magnetic
Resonance Imaging (MRI) is highly sensitive for primary lesion detection, particularly
for high risk women17. Specific MRI sequences such as diffusion weighted (DW) MRI
and dynamic contrast enhanced (DCE) MRI can provide further insight into tissue
architecture and vascularization within and around the tumor20,57. In particular, DCEMRI involves the injection of a contrast agent with small molecular weight, followed by
sequential imaging over the first ten minutes to assess extravasation of the agent from
vascular to interstitial spaces. Such imaging can illuminate tumor perfusion and
microvascular permeability58. Current clinical analysis of MR images is largely
qualitative, using DCE-MRI to identify tumor regions with contrast uptake or to monitor
morphologic appearance59. DCE-MRI offers advantages over other imaging methods that
can measure vasculature, including increased signal to noise ratio and spatial resolution,
and does not involve radiation exposure60.
10

Positron emission tomography (PET) imaging is most commonly clinically
performed for breast staging of stage IIIB/C or IV disease21. PET imaging can also be
used for staging patients with metastasis, or monitoring response to treatment61. PET
imaging works to detect radiotracer—a radioisotope paired with a molecule—
distribution in the body after injection. The most commonly used radiotracer in cancer
imaging is 18F-fluorodeoxyglucose, which pairs a glucose analog to the

18

F radioisotope.

Use of this radiotracer can provide insight into tumor metabolism as tumors have been
observed to utilize large amounts of glucose for energy generation through the anaerobic
process of glycolysis, known as the Warburg effect62. This is in contrast to normal tissue
which utilizes oxidative metabolism. Clinically, the most common quantitative parameter
derived from PET imaging is the standardized uptake value (SUV), or the estimated
amount of radiotracer per volume of radiotracer dose, scaled by patient weight. While
static imaging is most commonly utilized in the clinic, recent advances in PET
applications have demonstrated the added value of dynamic imaging of breast tumors22.
While other imaging modalities such as X-Ray and Ultrasound are implemented
in breast cancer clinical imaging21, they are used largely for screening purposes and are
not used as often as MRI for staging and treatment response monitoring due to radiation
exposure or poor spatial resolution. Computed tomography (CT) imaging is often paired
with PET imaging to provide a structural image in addition to the functional image.

2.4. Precision medicine and radiomic analysis
Precision medicine aims to tailor disease prognosis and treatment based on
specific genotypic and phenotypic characteristics of an individual. Recent advances in
11

medical image analysis have highlighted the implementation of computer vision
principles and analytic techniques used to quantify and describe medical images towards
precision disease prognosis and prediction24-27,33.
Image texture has been previously defined as repeating patterns of local variations
in gray-level intensities25,63. Texture analysis has most broadly been used to characterize
the spatial distribution of gray-level intensities within an image, capturing image patterns
usually unrecognizable or undistinguishable to the human eye. The original utilization of
texture analysis can trace back to computer vision applications for surface inspection and
orientation, image and object classification, and shape determination, while current
applications extend even beyond medical image analysis

63-65

. Within the scope of breast

imaging, texture analysis has emerged as a quantitative, surrogate measure for breast
parenchymal pattern when applied to images taken during mammographic and
tomographic screenings serving to augment conventional measures of breast percent
density in breast cancer risk assessment66.
Many studies aiming to analyze imaging presentations of breast lesions for
diagnostic, prognostic, and treatment applications have expanded the number and type of
features extracted to include morphology, texture, and pharmacokinetic features, allowing
for a thorough and quantitative characterization of all tumor properties. This has
developed into the new field of radiomics, broadly defined as the extraction of high
throughput quantitative features from images obtained from medical imaging modalities
28,67,68

. For the analysis of breast lesions, texture features are often extracted from a region

of interest (ROI) selected within a segmented lesion, or from the whole lesion itself.
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Additionally, recent studies have shown clinical associations of texture within the peritumor region as well, emphasizing the importance of the tumor microenvironment69,70.
The most commonly used radiomics features can be stratified by the statistical order of
the voxel information encoded within the image. Specifically, first order radiomic
features include common statistical measures derived from a gray-level histogram, such
as mean, median, and skewness. Second order radiomic features are often derived from
the co-occurrence matrix, as determined by Haralick et al.71, and the run-length matrix72,
while higher order radiomic features encode structural and frequency based texture
information (Figure 2.1.).
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Figure 2.1. Visual example of radiomic features. Representative 5 x 5 pixel image with 6 possible graylevels (0-5) (A). Gray-level histogram generated from representative image (B). Gray-level co-occurrence
matrix generated for 0˚. The co-occurrence matrix encodes the frequency that two pixels are located a
specific distance (1 pixel) away from one another (C). Run-length matrix generated for 0˚. Run-length
matrix encodes the coarseness of an image in a specified linear direction (D). This figure was adapted from
Chitalia et al. Journal of Magnetic Resonance Imaging, 2019.

2.5. First order: Gray-level histogram features
A gray-level histogram can be generated by calculating a frequency count of the
number of voxels of each gray-level intensity value, where the total number of discretized
gray-levels is often a user-selected parameter. From the resulting histogram, first order
statistical features may be derived, including the mean, median, and variance. Higher
moment features can also be extracted from the histogram including skewness, the
measure of the histogram distribution symmetry, and kurtosis, a measure of the histogram
14

distribution shape. While many descriptors can be extracted from the histogram, they
often provide cursory insight into the underlying texture, do not account for gray-level
intensity spatial relationships within an image, and are dependent upon user-selected
parameters. (Appendix Table A1)

2.6. Second order: Gray-level co-occurrence matrix and run length features
Gray-level co-occurrence matrix (GLCM) features are among the most commonly
extracted radiomics features for MR imaging quantification. A gray-level co-occurrence
matrix

encodes the frequency that two voxels of specific gray-level intensities are

positioned a specified distance away from each other in a specified image orientation

71

.

GLCM features are most often quantified in the four diagonal image orientations of 0°,
45°, 90°, and 135°. Second order features can then be extracted from the co-occurrence
matrix. Examples of such features include contrast, a descriptor of the intensity contrast
between a pixel and its neighbor as determined by the distance parameter, correlation, a
descriptor of the linear gray-level dependence, and homogeneity, a descriptor of the
closeness of distribution in the co-occurrence matrix to the matrix diagonal. Other second
order features such as energy, a descriptor of the certainty of gray-level co-occurrence
respectively, and cluster shade, a descriptor of asymmetry in gray-level values, can also
be extracted. Entropy, or the randomness of the GLCM, is another commonly extracted
feature, often indicating image heterogeneity (Appendix Table A2). Run-length features
measure the coarseness of an image in specified linear directions
A3).
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72-74

(Appendix Table

2.7. Higher order: Structural and transformation-based features
Structural features capture the intensity variations between central voxels and
surrounding neighboring voxels75 (Appendix Table A.4). Extending radiomic analysis
beyond the spatial orientation of gray-level intensity values, transformation based
radiomics features capture texture information encoded in a different space, such as the
frequency space. Transformation based methods include the Fourier transform, Gabor
transform, and Wavelet transform76-78. The wavelet transform, in particular, is commonly
used due to its ability to capture MR images’ frequency content both at varying image
scales and multiple specified directions.

2.8. Morphology features
Morphologic radiomic features aim to quantify the lesion’s physical
characteristics, either in 2-D or 3-D space. Such features may include volume, area, and
perimeter, as well as eccentricity, spiculation, or flatness. Variations of morphologic
features may account the entire lesion volume or consider only enhancing portions of the
tumor.

2.9. Radiomic analysis in breast lesions- MRI
Benefitted by the whole-tumor sampling and visualization of tumor vasculature
afforded by MRI, one of the largest aims in radiomics is to accurately characterize and
quantify intratumor heterogeneity

4,7,8

. As such, radiomic information extracted from

medical images can have high clinical relevance

79-87

. As compared to a global or

qualitative report of breast tumor appearance, radiomic analysis can provide a refined,
local description of tumor complexity, heterogeneity, and kinetic behavior as seen in
16

medical imaging. This quantitative characterization can have specific applications
towards the diagnosis, prognosis, and treatment of breast cancer. As MRI is the most
commonly utilized imaging modality for breast cancer diagnosis and treatment
management16,88, most advances in breast tumor radiomics have been implemented in
MR imaging34.

2.9.1. Radiomics applications in breast computer aided diagnosis
Computer aided diagnosis (CAD) of breast tissue was one of the earliest
applications of radiomic analysis in the breast

89

. Gibbs et al.

90

was one of the first to

apply radiomic analysis towards classifying breast lesions as benign or malignant. The
authors reported using 2D DCE-MR images from a cohort of 79 women, of which 45
were diagnosed with breast cancer. Within each lesion ROI, a co-occurrence matrix was
determined for adjoining pixels in 0°, 45°, 90°, and 135° directions. Radiomic features of
variance, sum entropy, and entropy were concluded to be the most significant when
discriminating between benign and malignant lesions, suggesting that features
quantifying image texture could be a useful tool in lesion delineation. Subsequent studies
have followed this preliminary, yet promising, conclusion by utilizing more complex
measures of image texture to diagnose breast lesions as benign or malignant

91-97

. This

idea was extended by Chen et al. 96, who extracted 3D GLCM features from a 3D breast
lesion segmentation. The 3D GLCM features yielded a higher diagnostic accuracy than
2D GLCM features extracted from a 2D ROI, when distinguishing between malignant
and benign breast lesions, showing an advantage for 3D breast lesion characterization.
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2.9.2. Beyond CAD: Radiomic analysis for histopathologic and molecular
subtype classification
The promising conclusions of MRI radiomic analysis in breast cancer diagnosis
suggests an architectural difference between the imaging presentation of benign and
malignant lesions that can be quantified using radiomic features. Recent studies have
begun extending this idea, hypothesizing that underlying tumor biological differences can
be imaged using MRI and characterized using radiomic analysis. Consequently, many
groups have employed radiomic analysis to distinguish between the heterogeneous
histopathologic 70,93,95,98 and molecular 99-102 subtypes of breast cancer, with a larger goal
of utilizing image texture features to provide a personalized diagnosis.
In an attempt to distinguish between Invasive Lobular Carcinoma (ILC) and
Invasive Ductal Carcinoma (IDC), Holli et al.

95

extracted a total of 277 histogram,

GLCM, run-length, and wavelet features. The authors found that of these, only GLCM
related features characterizing lesion complexity and randomness were significantly
different between ILC and IDC lesions. Similar conclusions were reported by Waugh et
al.98, who found that entropy, a measure of pixel distribution randomness, was
significantly different between lobular and ductal lesions, suggesting a difference in
underlying growth patterns and tumor heterogeneity.
Increasing the scope of radiomic analysis to include the surrounding
microenvironment in additions to the breast lesion, Wang et al.70 investigated the role of
kinetic contrast uptake texture in differentiating between histopathologic subtypes of
breast cancer. Radiomic features were extracted from pharmacokinetic parametric maps
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generated from DCE-MR images of the tumor and surrounding parenchyma. Adding
radiomic features characterizing heterogeneous uptake in the breast parenchyma to a
model containing lesion texture features allowed for the identification of triple negative
breast cancers (TNBC). The study concluded that the characterization of heterogeneity,
both within the lesion as well as the surrounding parenchyma, could provide noninvasive
insight towards heterogeneous tumor behavior associated with more aggressive subtypes.
These results were similar to those found in previous studies 103,104, indicating the clinical
value of lesion and peri-tumoral contrast uptake quantification. Radiomic features
quantifying lesion heterogeneity have also shown to aid in delineating between molecular
subtypes of breast cancer. Studies have shown a radiomic difference between the MR
presentation of luminal A and luminal B subtypes, with luminal B lesions having a more
quantifiably heterogeneous appearance99,102.

2.9.3. Radiomic analysis for breast cancer prognosis and therapy response
prediction
Recent studies have shown promising conclusions when exploring the
relationship between breast lesion appearance and risk of recurrence, and the value
radiomics as a non-invasive prognostic biomarker

93,105-109

. Kim et al. performed a

retrospective analysis of 203 women diagnosed with invasive breast cancer, extracting
histogram uniformity and entropy features from both T2-weighted MR images and T1weighted DCE-MRI. Univariate and multivariate associations between these texture
features and disease-free survival determined that increased tumor heterogeneity in T2weighted MRI could be used to stratify patients more at risk for recurrence. This study
suggested that tumor heterogeneity, as quantified by lesion texture, could be used in MR
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imaging as an independent prognostic marker. Similar conclusions were drawn by Park et
al.

107

who generated a multivariate feature vector based on morphologic, histogram

texture, and GLCM texture features, from which specifically GLCM cluster tendency,
GLCM variance, and GLCM sum variance were selected for in a model stratifying
patients at risk for recurrence. Mahroongy et al.

108,109

extracted wavelet features from

within tumor sub-regions partitioned by pharmacokinetic behavior and concluded that the
spatial frequency texture pattern captured using wavelets within the heterogeneous subregions could serve as a strong prognostic biomarker for predicting risk of tumor
recurrence (AUC= 0.88).
The potential for radiomic analysis in breast cancer treatment has been
demonstrated in recent studies, showing the potential for MRI-extracted radiomic
features to serve as non-invasive predictive biomarkers

69,73,104,105,110-120

. In order to

predict response to treatment, some studies utilize first-order statistical measures
extracted from the tumor ROI. Specifically, Johansen et al.

119

calculated three first-order

statistical features of mean, standard deviation, and prediction from a relative signal
intensity histogram generated from pre-chemotherapy DCE-MRI scans. Of these,
skewness and kurtosis were found to be strongly correlated with complete response to
therapy. Similarly, Padhani et al.

120

conducted a retrospective study of 25 women

diagnosed with primary invasive cancer, imaged using DCE-MRI before and after the
first cycle of treatment. Leveraging contrast enhancement, the authors generated a
histogram from a pharmacokinetic parametric map of the full lesion ROI, and concluded
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that responsive patients displayed a decrease in pharmacokinetic range, and proposed that
this could be attributed to a decrease in heterogeneity after the first cycle of treatment.
While histogram texture can provide useful information regarding the distribution
of gray-level intensity values, it is limited when capturing spatial heterogeneity within a
lesion as it largely ignores the spatial relationships between voxels. Studies extracting
higher-order radiomic features can further quantify the relation between tumor
heterogeneity and response to therapy. To this end, Teruel et al. extracted second-order
statistical GLCM features from pharmacokinetic maps generated from DCE-MRI images
of women diagnosed with locally advanced breast cancer. Eight GLCM features were
found to significantly differ between responders and non-responders, and GLCM sum
variance was able to predict response to treatment with an AUC of 0.77.
conclusions were drawn by Thibault et al.

111

Similar

, who expanded this 2D analysis by

extracting 3D GLCM features from DCE-MR pharmacokinetic parametric maps in order
to predict response to neo-adjuvant chemotherapy (NAC). The 3D GLCM features were
particularly significant in identifying early responders to NAC, with results showing nonresponders having higher microvascular heterogeneity. In a retrospective study of 36
women who underwent NACT, the change in tumor heterogeneity between pre-treatment
and mid-treatment, as calculated by entropy and uniformity changes, was predictive of
pCR with an AUC of 0.84

113

. Comparing this performance to change in tumor size

(AUC= 0.66) demonstrates a greater sensitivity for lesion texture in characterizing early
response to pCR.
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Current clinical predictions for achieving pathologic complete response (pCR) are
based on tumor histopathologic characteristics. As intratumor heterogeneity is associated
with adverse clinical outcomes, the limited tissue taken during biopsy may be inadequate
for a whole tumor based prediction

7,8

. Michoux et al.

114

performed a retrospective

analysis on the DCE-MR scans of sixty-nine patients diagnosed with IDC, undergoing
NAC. For each woman, texture, kinetic, and morphology-based features were extracted
from within the pre-treatment lesion ROI. The authors concluded that only four
parameters—three

features

(GLCM

inverse

difference

moment,

grey-level

nonuniformity, and long run high gray level emphasis), and the wash-in slope kinetic
feature —were found to classify non-responders with 84% sensitivity. Of particular note,
clinically utilized histopathologic predictive biomarkers such as estrogen receptor (ER)
status, progesterone receptor (PR) status, Ki67 status, and human epidermal growth factor
receptor 2 (HER2), along with tumor grade, were not significant when classifying early
response, further highlighting the utility of radiomic analysis. Similarly, Golden et al.

112

extracted GLCM based features from pharmacokinetic parametric maps generated from
DCE-MR images of women diagnosed with TNBC, in order to predict pCR, residual
lymph node metastases, and residual tumor with lymph node metastases. The predictive
performance of GLCM texture features was compared to ‘patterns of response’, a
qualitative description of lesion appearance before and after chemotherapy, as determined
by a radiologist. The GLCM features extracted from pre-chemotherapy MR images could
predict pCR and residual lymph node metastasis with a reported AUC of 0.68 when
classified in a logistic regression model. In contrast, the radiologist determined ‘patterns
of response’ did not predict any of three outcome measures.
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The conclusions drawn from studies implementing radiomic analysis for breast
cancer diagnosis, prognosis, and treatment suggest that radiomic features demonstrating
increased lesion heterogeneity are associated with aggressive growth, unfavorable
prognosis, and poor treatment outcomes69,105,109,115,121-123. In addition, they propose a
method for non-invasively quantifying the underlying biology of tumor sub-regions
driving recurrence, response, and resistance to therapy (Figure 2.2).

Figure 2.2 Representative images of a non-recurrent and recurrent breast tumor. (A). Examples of texture
features maps showing distributions of histogram texture features (B), co-occurrence matrix texture
features (C), and structural texture features (D). This figure was adapted from Chitalia et al. Journal of
Magnetic Resonance Imaging, 2019.

2.10. Novel applications of breast radiomics
While most advances in radiomic analyses of breast cancer have been made
utilizing MRI images, there are few studies investigating radiomic analysis of molecular
imaging modalities such as PET124. For the diagnosis of breast lesion as benign or
23

malignant, Vogl et al. investigated MRI and PET radiomic features. The author found
that only MRI-based texture features were predictive in lesion classification. Conversely,
Ou et al. found that SUV and radiomic features from FDG PET could stratify breast
cancer from breast lymphoma125.
As PET imaging leverages biologically targeted radiotracers, radiomic analysis of
PET imaging has been used for the biological characterization of breast tumors.
Lemarignier et al. found that radiomic features of image texture extracted from FDG
PET imaging were significantly associated with histological subtypes of breast cancer126.
However, other studies looking at associations between radiomic features from FDG PET
and histological subtypes found no significant associations127-130. Studies have also
examined the correlation between PET radiomic features and molecular subtypes of
breast cancer128,130-132, finding associations between features and receptor status131,133, and
proliferative status129.
PET radiomic analysis has also been explored for treatment response prediction.
Numerous studies have found associations between PET-derived radiomic features and
pathological complete response to NCT129,132,134-136. Lastly, PET radiomic analysis has
been utilized to predict patient outcome including progression-free survival (PFS)136,
disease-free survival (DFS)132, overall survival (OS)127, and recurrence-free survival
(RFS)128.
While DCE imaging and PET imaging are not utilized as often as other modalities
for breast cancer screening, recent studies have suggested associations between radiomic
24

analysis and characterizations of the whole breast, such as background parenchymal
enhancement (BPE) from DCE-MRI137-139. With respect to personalized breast cancer
diagnosis and treatment response monitoring, studies have demonstrated that increasing
the scope of radiomic analysis to include surrounding BPE within the peri-tumoral region
has allowed for improved diagnostic and predictive performance69,70,140,141. Mazurowski
et al.140 demonstrated that radiomic features characterizing the texture and
pharmacokinetic behavior of breast lesions and the surrounding parenchyma were highly
associated with the luminal B subtype, suggesting that quantitative characterization of
BPE could provide personalized diagnoses. Similar conclusions were reported by Wang
et. al 70, where features characterizing texture were extracted from pharmacokinetic maps
generated from DCE images of the tumor and surrounding parenchyma. Augmenting a
classification model of lesion radiomic features with BPE radiomic features improved
performance for the identification of triple negative breast cancers (TNBC). Radiomic
analysis has the potential to provide quantitative insight into parenchymal enhancement
patterns to further understand the role of BPE in personalized clinical decision making.
Leveraging high-throughput genomic, molecular, and sequencing data alongside
imaging data may provide complementary insight into patient-specific diseases for the
improvement of precision cancer care. This has developed into the field of
“radiogenomics”, which aims to find associations between imaging and genomic streams
of information for the combined prediction of patient outcomes and the biological
interpretation of imaging features142,143. Advances in breast tumor radiomics has led to
associations between radiomic signatures and molecular subtypes144-146, combined
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radiogenomic models for outcome prediction101,147,148, and radiomic signatures correlated
with biological pathways123,149-151.

2.11. Radiomic analysis study designs
Effective use of radiomic analysis on medical images of breast cancer is highly
dependent upon appropriate study design and statistical evaluation. There are numerous
methods for radiomic feature extraction, resulting in a myriad of ways to quantify an
image’s texture. Consequently, having a high-dimensional radiomic feature set as
compared to a relatively smaller sample size can result in the overfitting of a statistical
learning model, resulting in false positive classification and over- or under- estimated
statistical associations. Additionally, redundant radiomic features can often decrease
performance accuracy. To alleviate this, methods such as principal component analysis or
independent component analysis can be used to reduce the dimensionality of the radiomic
feature set152. Feature selection methods can also be used to reduce radiomic feature
redundancy and promote relevant features for analysis. Statistical correction methods,
such as the Benjamini-Hochberg correction153, can be used to reduce false positives in
statistical association conclusions. Ideally, results should be validated using an
independent dataset, to ensure veracity of the radiomic analysis. While finding
comparable independent datasets is not always feasible, splitting the initial dataset into
discovery and validation sets is an alternative solution to ensure repeatability. Similarly,
cross-validation can be used to identify robust conclusions. Lastly, utilization of publicly
available datasets and detailed methodology of specific radiomic parameters used during
feature extraction, can allow for study repeatability.
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2.12. Future Directions
Radiomic analysis is currently limited by user-defined feature parameters, such as
selecting the number of discretized gray-levels within an image, image acquisition
protocol, and image quality25,96,154. As such, literature largely lacks repeated studies
performed on the same datasets with standardized radiomic feature extraction.
Additionally, while radiomic features provide quantitative measures of breast tumor
texture, the direct biological interpretation of specific radiomic feature values remains
largely uncertain. Leveraging the specific properties of various functional MRI and PET
imaging techniques, radiomic analysis can be used to quantify different tissue properties.
Radiomic analysis applied to DCE-MRI or DW-MRI could provide insight on the
distribution or longitudinal development of tumor vascularization and diffusion,
respectively. Radiomic analysis applied to PET images utilizing biologically targeted
radiotracers could provide insight into specific tumor physiology. Similarly, statistical
associations between image derived radiomic features and histopathologic or genomic
expression data could allude to a biological basis for tumor imaging presentations.
Further work is needed to explore the relationships between specific radiomic features
and underlying biology. Additionally, leveraging radiomic information from alternative
imaging modalities in combination with that acquired from MRI could augment breast
tumor characterization155.

Advances in computational processing power such as

increased memory and GPUs, have allowed for implementation of deep learning
architectures for the analysis of breast tumors. Deep learning has the potential to use
automated features and provide insights beyond “hand-crafted” radiomic features, which
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are dependent upon user derived parameters. Using such technology however requires
large datasets for training and may lack interpretability due to the higher order nature of
resulting prognostic or predictive features.
Moving forward, computational medical image analysis has the potential for use
in fully characterizing tumor biology to serve as a non-invasive quantitative tumor assay,
complementing proteomic and genomic tumor analyses for a more comprehensive and
personalized understanding of breast cancer.
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Chapter 3 : Spatial heterogeneity in dynamic contrast enhanced
magnetic resonance imaging
This chapter has been adapted from the following:

Chitalia, R.D., Rowland, J., McDonald, E.S., Pantalone, L., Cohen, E.A., Gastounioti,
A., Feldman, M., Schnall, M., Conant, E. and Kontos, D., 2020. Imaging phenotypes of
breast cancer heterogeneity in preoperative breast dynamic contrast enhanced magnetic
resonance imaging (DCE-MRI) scans predict 10-year recurrence. Clinical Cancer
Research, 26(4), pp.862-869.

3.1. Introduction
This chapter provides details of exploring spatial heterogeneity in DCE-MRI
images of breast tumors at baseline. We identify imaging phenotypes and aim to
understand their relationship with conventional prognostic markers and patient outcomes
to propose a non-invasive assessment of cancer.
Currently, critical disease treatment decisions are made on the basis of biomarkers
acquired from tissue samples, typically obtained via core biopsy or surgical excision.
Histopathologic assessment of this sample determines common prognostic markers
including tumor size, shape, grade, nodal status, and metastasis. The prognostic and
predictive markers derived from the limited diagnostic tissue samples may under-sample
spatially heterogeneous breast tumors as well as overlook temporal shifts due to breast
cancer progression or exposure to therapy. Therefore, there is a clinical need to develop
prognostic and predictive markers of intratumor heterogeneity that may augment
established biomarkers for personalized disease diagnosis, staging, management, and to
assess treatment response to neoadjuvant therapy.
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Medical imaging is currently used for breast cancer diagnosis, staging, and
treatment response assessment, providing a means for longitudinal, non-invasive, wholetumor evaluation of disease burden16,17,57. Dynamic contrast enhanced magnetic
resonance imaging (DCE-MRI), in particular, is highly sensitive for primary lesion
detection and staging, with the ability to assess tumor vascularization with contrast
enhancement17,20. The field of “Radiomics” has shown promise in quantifying the
imaging presentation of underlying tumor biology8,28,101,109,116,156. Identifying intrinsic
radiomic phenotypes of breast cancer and understanding their relationship with patient
outcomes and other histopathologic factors could complement conventional prognostic
and predictive biomarkers. The purpose of this study was to identify and validate such
intrinsic DCE-MRI radiomic phenotypes of breast cancer tumor heterogeneity and
evaluate their independent prognostic performance in predicting 10-year recurrence, and
their performance in augmenting established, histopathologic prognostic factors.

3.2. Discovery cohort: Study population and imaging protocol
Breast DCE-MRI scans were retrospectively analyzed from a previously
completed, multimodality imaging trial conducted at our institution (2002- 2006;
National Institutes of Health; P01CA85484) designed to evaluate an array of different
breast imaging modalities in cancer staging, diagnosis, and screening. The study was
Health Insurance Portability and Accountability Act-compliant, approved by the
institutional review board at our institution, and in accordance with U.S. Common
Rule. The trial originally recruited 901 women, including women with newly diagnosed
breast cancer presenting for staging, women with a mammographically detected
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suspicious finding or suspicious palpable mass directed to biopsy, and women eligible for
high-risk screening. Informed written consent was obtained prior to trial participation.
From these, 317 women were diagnosed with primary breast cancer, of which 231 were
diagnosed with invasive breast cancer. From this subset of 231 women, 177 women had
DCE-MRI images available for analysis. An additional 72 women were excluded for not
receiving a consistent imaging protocol of fat-suppressed, T1-weighted DCE-MRI with at
least two post contrast scans available for analysis. Lastly, 3 women were excluded on
the basis of image quality, determined by biopsy artifacts and fiduciary markers, or the
presence of diffuse disease in order to prevent inaccurate ROI segmentation, and 7
women were excluded due software algorithm output resulting in incomplete values
during radiomic feature extraction. Therefore, a total of 95 women diagnosed with
primary invasive breast cancer and imaged with a consistent T1-weighted DCE-MRI
protocol with a first and second post-contrast acquisition, prior to any treatment, were
included in our analysis. For this retrospective analysis, the requirement of informed
consent was waived under institutional review board approval.
Following intravenous administration of gadolinium contrast, DCE-MRI images
were acquired sagitally via a T1-weighted 3D protocol. Images were acquired with a 45degree flip angle over a 16-18 cm field of view, with 2-2.5 mm slice thickness. Women
subsequently underwent surgery for tumor removal. Histopathologic analysis of surgical
specimens evaluated hormone receptor (HR) status, consisting of ER and PR status,
HER2 status, clinical stage, size (cm) as determined from pathology sample, and surgical
margins. Stage, Modified Bloom Richardson grade (MBRG), lymph invasion status,
nuclear grade, and presence of ductal carcinoma in situ (DICS) were also documented.
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Post-surgery therapy included a variable combination of chemotherapy, hormone therapy,
and radiation. Recurrence-free survival (RFS) was monitored for all women over a 10year follow-up period. Survival was determined as the date of breast cancer diagnoses to
death or more recent follow-up. Patients without an event were censored at the date of
last follow-up. In the discovery cohort, 11 women (12%) had recurrence events, and 84
women (88%) were event-free until their last available follow-up (Table 3.1). Clinical
stage was statistically significantly associated with recurrence events (p = 0.02) (Table
3.1).
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Table 3.1. Summary of patient characteristics from the discovery cohort.
Primary Invasive Cancers
(n=95)
Non-recurrent
cases at the time
of last follow-up

Recurrent cases
11 (12%)

Significance
tested using
Chi-square
analysis

84 (88% of total)
Malignant Pathology

p=0.48

Invasive Ductal Carcinoma
(IDC)

65 (77% of NR)

8 (73% of R)

Invasive Lobular Carcinoma
(ILC)

8 (10%)

1 (7%)

IDC/ILC

9 (11%)

2 (14%)

Receptor Status

p= 0/37

Hormone Receptor Positive

61(73%)

9 (82%)

HER2 Positive

20 (24%)

2 (18%)

Triple Negative

11 (13%)

1 (9%)

Clinical Stage

p=0.02

Early Stage (1)

35 (41%)

1 (9%)

Advanced Stage (2-3)

45 (54%)

10 (91%)

DCIS
Present

p=1
67 (80%)

9 (82%)

Margins

p=0.07

Positive

40 (48%)

6 (55%)

Negative

40 (48%)

5 (45%)
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3.3. Validation cohort: Study population and imaging protocol
An independent validation cohort was acquired from a subset of the ISPY1/ACRIN 6657 trial (2002-2006)157. Women diagnosed with T3 breast tumors measuring
3cm or larger were enrolled in this trial, and underwent anthracycline-based neoadjuvant
chemotherapy. DCE-MRI scans were acquired for women in this study as previously
described158. The pre-treatment and pre-operative DCE-MRI images of 222 women were
publicly available via The Cancer Imaging Archive159. From this, 15 women were
excluded for having incomplete DCE acquisition or variability in imaging protocol. A
further 43 women were excluded for having missing histopathologic data, RFS outcome,
or pre-treatment DCE-MRI scans, and 1 woman was excluded due software algorithm
output resulting in incomplete values during radiomic feature extraction. In all, 163
women were included in the validation cohort for this study; validation analysis utilized
the scans that were both pre-treatment and pre-operative. Clinical information including
HR status and HER2 status were available for each woman in the validation cohort. RFS
status, defined as the time between first chemotherapy treatment and disease recurrence,
was also available. A total of 44 women in the validation cohort (27%) had recurrent
tumors (Table 3.2). A comparison between the two cohorts via chi-square analysis
indicated a statistically significant difference between number of recurrent cases (p =
0.02), number of HR positive cases (p = 0.02), and clinical stage of tumors (p < 0.001)
(Table 3.2).
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Table 3.2. Summary of patient characteristics from the validation cohort (a). Statistical
comparison between discovery and validation cohorts for covariates common in the two
datasets (b).

3.4. Radiomic feature extraction
For each woman in the discovery cohort, the primary lesion was selected by a
radiologist from the pre-treatment, pre-operative DCE-MRI scan, and manually
segmented from the most representative slice, as determined by the largest tumor volume.
This manual segmentation served as the initialization for 3-D tumor volume
segmentation, which was performed using a previously validated, automated method160
and visually verified by an expert after segmentation. Images were pre-processed using
N3 bias-field normalization161 and histogram normalization in order to correct for low
frequency bias field signal or outliers that may induce artifacts within the image. Using
the first (I1) and second (I2) post-contrast images, a signal enhancement ratio (SER) map
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was generated(23) for the entire tumor volume, defined as the voxel-wise ratio between
the first and second post contrast images:
Eq. 3.1

The first and second post-contrast images were acquired in succession at an average
approximation of 90 seconds after contrast injection and first-post contrast scan,
respectively. A multi-parametric, radiomic feature vector was extracted from the SER
map for each woman, including a) previously validated morphologic features of tumor
perimeter, area, ellipticity, and convexity, shown to be associated with disease
progression20,162, and b) radiomic features capturing structural75, run-length72-74, cooccurrence matrix71, gray-level histogram, and gray-level size zone matrix textures111,
which were extracted and summarized over the primary lesion. Briefly, structural features
capture intensity variations between central voxels and neighboring voxels. Run-length
features measure the coarseness of an image in specific linear directions. Co-occurrence
features analyze the spatial distribution of voxel intensity values by capturing frequency
information of gray-level intensity values within a neighborhood of voxels in a specific
linear orientation. Gray level histogram features are first order statistical features
assessing the distribution of gray-level voxel intensities within an image. Gray level size
zone features capture the connectedness of varying intensity levels within an image.
Additionally, the mean and standard deviation of SER values of the tumor were
calculated. Consequently, a total of 60 radiomic features were extracted. All features
were extracted using the publicly available software, Cancer Imaging Phenomics Toolkit
(CaPTk) (ver. 1.7.1, Univ. of Pennsylvania) (https://cbica.github.io/CaPTk/) 163.
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3.5. Discovery of intrinsic imaging phenotypes
Prior to phenotype identification, the multi-parametric radiomic features extracted
from the pre-operative DCE-MRI scans were z-score normalized164. Furthermore, zscored features with extreme skewness or extremely low variations in distributions across
women, defined as interquartile range (IQR) < 1 or kurtosis > 15, were excluded from
further analysis to prevent a biased analysis. This resulted in a total of 22 features
concatenated to form the final feature vector. Given the definition of each radiomic
feature in the final feature vector, features were standardized such that a greater feature
value indicates greater image heterogeneity. A tumor heterogeneity index was then
generated for each woman, defined as the statistical average of z-score normalized,
standardized features in the final feature vector. Thus, a higher heterogeneity index
corresponds to higher intratumor heterogeneity whereas a lower heterogeneity index
corresponds to increased intratumor homogeneity.
To identify intrinsic imaging phenotypes, unsupervised hierarchical clustering
was performed on the extracted, multi-parametric feature vectors for women in the
discovery cohort36. The k clusters obtained from the unsupervised hierarchical clustering
algorithm are interpreted as intrinsic imaging phenotypes in the population. Briefly, an
agglomerative approach was used to create a hierarchical clustering of women, using
Euclidean distance for the distance between feature vectors and Ward’s minimum
variance method as the clustering criterion165. The optimal number of distinct
phenotypes, k, was determined by assessing the stability and significance of each
phenotype for each value of k that was considered. The optimal number of stable
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phenotypes was determined using consensus clustering166, where the dataset was
subsampled and cluster arrangements were determined using varying numbers of k. For
each number of k phenotypes, the proportion that two women occupied the same
phenotype cluster out of the number of times they appeared in the same subsample was
determined and stored in a symmetric consensus matrix, from which a cumulative
distribution function (CDF) was determined. Cluster stability, as determined by the area
under the CDF curve, was evaluated for each increase in k phenotype, with a change in
stability less than 10% deemed insignificant. Statistical significance of the identified,
stable phenotypes was evaluated using the SigClust method167. Here, the significance of
the cluster index, defined as the sum of within- cluster sums of squares about the clustermean divided by the total sum of squares about the overall mean, was tested against a
null distribution, simulated using 10,000 samples from a Gaussian distribution fit to the
data. The test was performed at each phenotype split to determine statistical significance
(p<0.05).

3.6. Independent validation of intrinsic imaging phenotypes
Tumor segmentation for cases from the validation cohort was performed per the
ISPY-1/ACRIN 6657 protocol158. The 22 features identified from the discovery cohort
were extracted from segmented tumors in the validation cohort using the same feature
pre-processing steps outlined above, to form the final feature vectors for hierarchical
unsupervised clustering analysis. These features were normalized using the mean and
standard deviation values of each respective feature’s distribution in the discovery cohort,
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to standardize feature ranges. To validate identified phenotype reproducibility, women in
the validation cohort were assigned to the discovery cohort- identified phenotypes by
minimizing the Euclidian distance between each validation cohort feature vector and the
discovery cohort-identified phenotype centroid. The significance and reproducibility of
phenotype assignment in the validation cohort was assessed using Consensus Clustering
and the SigClust methods (Figure 3.1).
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Figure 3.1. Study design. Radiomic features were extracted from SER maps generated from preoperative
DCE-MRI scans from women in the discovery cohort (n = 95). Feature selection resulted in a 22-feature
feature vector. Unsupervised hierarchical clustering was used to identify intrinsic imaging phenotypes,
which were assessed for statistical significance and stability. The same 22 features were extracted from the
preoperative DCE-MRI scans of 163 women in an independent validation cohort. Women in the validation
cohort were assigned to a phenotype identified in the discovery cohort by minimizing the distance between
their 14-feature feature vector and the corresponding phenotype centroids. The independent and additional
prognostic values of heterogeneity phenotypes were assessed via Kaplan–Meier RFS analysis and Cox
proportional hazards models when compared with a baseline model of established histopathologic
biomarkers.
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3.7. Prognostic value of imaging phenotypes
We assessed the distribution of histopathologic, prognostic covariate values for
women assigned to each heterogeneity phenotype using chi-square tests for categorical
biomarker values and Kruskal-Wallis tests for continuous biomarker values. The
distributions of post-surgery therapy received by each woman (i.e., chemotherapy,
hormone therapy, and radiation therapy) and recurrence-free survival were assessed
across phenotypes to identify any associations between therapy and RFS or heterogeneity
phenotypes.
RFS probabilities across heterogeneity phenotypes within the discovery and
validation cohorts were evaluated using Kaplan-Meier curves, with log-likelihood
statistical tests used to assess their significance and determine their independent
prognostic value. To determine the additional value categorizing tumor heterogeneity
phenotypes, a baseline Cox proportional hazards model was built using the established
histological prognostic factors of HR and HER2 status. Performance of this model in
predicting RFS was tested both with and without phenotype cluster assignment, coded as
a categorical variable.

3.8. Study results: Discovery of intrinsic imaging phenotypes
Three statistically significant phenotypes were identified in the discovery cohort
via unsupervised hierarchical clustering and found to be statistically significant via the
SigClust methods (p < 0.01) (Figure 3.2). Ordering the heterogeneity indices of the
corresponding centroids for the identified phenotypes in ascending order allowed for the
identified phenotypes to be interpreted as phenotypes of low, medium, and high
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intratumor heterogeneity (Figure 3.3). The number of recurrences were statistically
significantly different across the heterogeneity phenotypes via chi-square analysis (p =
0.01).
Kaplan-Meier RFS curves for women stratified by heterogeneity phenotype
assignment were found to be statistically significantly different, as determined using the
log-rank test (p < 0.05). A baseline Cox-proportional hazards model consisting of HR
status and HER2 status resulted in a c-statistic of 0.55 when predicting 10-year RFS.
Adding heterogeneity phenotype assignment to the baseline model resulted in a c-statistic
of 0.73 A log-likelihood test showed statistically significant improvement in the
augmented model performance (p = 0.007) (Figure 3.2).
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Figure 3.2. Identification of intrinsic imaging phenotypes of tumor heterogeneity. Unsupervised
hierarchical clustering of SER features identifies three intrinsic phenotypes in the discovery cohort (A).
RFS curves for women stratified by imaging heterogeneity phenotype show that heterogeneity phenotype is
statistically significant (P < 0.05) when predicting RFS (B). Adding phenotype information to Cox
regression model shows an improvement in c-statistic when predicting recurrence events (C).
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Figure 3.3. Representative cases from heterogeneity phenotypes. Representative slice, tumor region, and
SER map from a pre-menopausal woman diagnosed with primary stage-I, HR+, HER2- , node-negative
breast cancer assigned to the low heterogeneity phenotype (top), a peri-menopausal woman with primary
stage-II, HR-, HER2+, node- negative breast cancer assigned to the medium heterogeneity phenotype
(middle), and a pre-menopausal woman with primary stage-II, ER-, HER2-, node-positive breast cancer
assigned to the high heterogeneity phenotype (bottom).

Analysis of clinical covariate significance across heterogeneity phenotype status
showed that differences in tumor MBRG, estrogen receptor percentage, and tumor
mitotic stage were statistically significant across heterogeneity phenotypes (p = 0.03,
p=0.001, and p=0.02, respectively). Of poorly differentiated (MBRG 8-9) tumors, 80%
were assigned to the medium or high heterogeneity phenotypes, and 20% were assigned
to the low heterogeneity phenotype (Figure 3.4a). Tumors assigned to the low and
medium heterogeneity phenotypes had median estrogen receptor percentages of 75% and
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70% respectively, while tumors assigned to the high heterogeneity phenotype had median
estrogen receptor percentages of 40% (Figure 3.4b). Of tumors with high mitotic stages,
81% were assigned to the medium or high heterogeneity phenotypes, and 19% were
assigned to the low heterogeneity phenotype (Figure 3.4c).

Figure 3.4. Associations between histopathologic prognostic markers and heterogeneity phenotypes.
Associations between histopathologic prognostic markers and heterogeneity phenotypes identified in the
discovery cohort. Degree of phenotypic heterogeneity in well, moderately, and poorly differentiated tumors
(A). Percent of estrogen receptor distribution for women in low, medium, and high heterogeneity
phenotypes (B). Degree of phenotypic heterogeneity in tumors with low, moderate, and high mitotic stage
(C).
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3.9. Study results: Validation of intrinsic imaging phenotypes
Women in the discovery cohort assigned to the low, medium, and high
heterogeneity phenotypes had average heterogeneity indices of -0.09, -0.03, and 0.16,
respectively (Figure 3.5a). Women in the validation cohort assigned to the low, medium,
and high heterogeneity phenotypes had average heterogeneity indices of -0.05, -0.24, and
0.21, respectively (Figure 3.5b).

Figure 3.5. Heterogeneity index* distributions of women in low, medium, and high heterogeneity
phenotypes in the discovery (A) and validation (B) cohorts. *Defined as the statistical average of z-score
normalized, heterogeneity standardized features in the final feature vector for each tumor in the discovery
and validation cohorts.

The heterogeneity phenotypes were found to be reproducible and statistically
significant in the validation set using the SigClust methods (p = 0.01). Kaplan-Meier RFS
curves for women stratified by phenotype clustering assignment were statistically
significantly different (p = 0.01) (Figure 3.6). A baseline Cox-proportional hazards model
consisting of HR status and HER2 status resulted in a c-statistic of 0.61 when predicting
10-year RFS. Adding heterogeneity phenotype assignment to the baseline model resulted
in a c-statistic of 0.67 A log-likelihood test showed statistically significant improvement
in the augmented model performance (p = 0.01).
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Analysis of clinical covariate significance across heterogeneity phenotype status
showed that differences in progesterone receptor status were statistically significant
across heterogeneity phenotypes (p = 0.03).

Figure 3.6. Independent validation of intrinsic imaging phenotypes of tumor heterogeneity. Phenotypes
identified in the discovery cohort are significantly reproducible in the validation cohort (A). RFS curves for
women stratified by imaging heterogeneity phenotype show that heterogeneity phenotype is statistically
significant (p = 0.01) when predicting RFS (B).

3.10. Discussion
Our results indicate that distinct imaging phenotypes exist within invasive breast
tumors which correspond to different degrees of intratumor heterogeneity, suggesting that
radiomic features can non-invasively characterize such heterogeneity patterns. The
identification and validation of distinct image heterogeneity phenotypes show that the
phenotype clusters identified are both interpretable and meaningful. Most notably, the
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validated heterogeneity phenotypes show independent prognostic value when predicting
10-year RFS, indicating that intrinsic imaging phenotypes can potentially identify
intratumor heterogeneity features driving aggressive tumor behavior. Women assigned to
the high heterogeneity phenotype demonstrated decreased probabilities of RFS over the
10-year follow-up period, corroborating the hypothesis that heterogeneous tumors are
associated with aggressive tumor behavior and treatment resistance.
Of particular note, the medium heterogeneity phenotype encompasses a wide
range of tumors, as evidenced by the differences in Kaplan-Meier survival analysis
between women assigned to the medium heterogeneity phenotype in the discovery and
validation cohorts. While both cohorts represent populations of women diagnosed with
invasive breast cancer, all women in the validation cohort were diagnosed with advanced
stage disease, and therefore eligible for neoadjuvant therapy. As the discovery cohort
consists of more diverse disease stages, women in the validation cohort assigned to the
low heterogeneity phenotype may have higher degrees of tumor heterogeneity as
compared to women in the discovery cohort also assigned to the low heterogeneity
phenotypes and may therefore be more similar to tumors assigned in the discovery cohort
as having a medium heterogeneity phenotype. This is supported by the similarity of the
average heterogeneity indices for women in the validation cohort assigned to the low
heterogeneity phenotype versus women in the discovery cohort assigned to the medium
heterogeneity phenotype (-0.05 and -0.03, respectively). Consequently, survival
probabilities for women in the validation cohort assigned to the low heterogeneity
phenotype may be more similar to women in the discovery cohort originally assigned to
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the medium heterogeneity phenotype, as compared to women in the low heterogeneity
phenotype. A statistical comparison between cohorts suggests women in the validation
cohort had a statistically significantly higher proportion of HR negative tumors, thereby
suggesting more aggressive tumor behavior and outcome (Table 3.2).
Imaging phenotypes of intratumor heterogeneity also provide additional
prognostic value when augmenting established histopathologic prognostic biomarkers.
The independent and additional prognostic value of phenotype assignment suggests that
imaging phenotypes can provide unique information about underlying tumor behavior,
and therefore, complement clinically utilized prognostic markers for personalized
prognosis and decision making.
Higher degrees of imaging phenotype heterogeneity were shown to be associated
with poorly defined tumors as per the MBRG and tumors with higher mitotic grades. The
increased mitotic grade of tumors in the higher heterogeneity phenotypes may contribute
to the genetic diversity and sub-clonal evolution thought to increase intratumor
heterogeneity39. These results suggest that tumor characteristics such as nuclear
pleomorphism and increased mitotic rates, which are characteristic of aggressive tumor
behavior, may be captured by the imaging phenotypes of tumor heterogeneity.
Additionally, tumors with lower percentages of estrogen receptors displayed statistically
significantly higher imaging phenotype heterogeneity, correlating with established
hypotheses that estrogen positive tumors are associated with more positive
prognoses168,169. The statistically significant associations of histopathologic prognostic
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covariate distributions across heterogeneity phenotypes indicate that image heterogeneity
may correlate with underlying tumor biology.
We have identified intrinsic imaging phenotypes of intratumor heterogeneity in
primary invasive breast cancer that can independently predict 10-year recurrence and
have validated these findings in an independent cohort. While previous studies have
utilized hierarchical clustering analysis to identify imaging phenotypes or have
investigated relationships between radiomic features and histopathologic and genomic
tumor characteristics, most of these studies have used surrogate measures of recurrence
or were limited by a lack of independent validation101,147.
Limitations to our study should be noted. For this exploratory analysis, we chose
a fixed set of radiomic features. The independent validation cohort utilized for this study
consisted of only advanced stage tumor diagnoses with a limited availability of
histopathologic prognostic biomarkers, as opposed to the discovery cohort which
consisted of both early and advanced stage tumors and a wide array of histopathologic
prognostic biomarker information available for each woman. As both cohorts included
women diagnosed with invasive breast cancer and follow-up information, we determined
that validating our heterogeneity phenotypes with a more niche cohort can still
demonstrate the added value and generalizability of tumor imaging heterogeneity
phenotypes. Additionally, we limited the histopathologic prognostic biomarkers used for
baseline model regression analysis of the discovery cohort to match those covariates
available in the validation cohort. Future work will aim to expand this analysis to a larger
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cohort. Lastly, we will seek to further explore the added prognostic value of imaging
phenotypes to that of emerging prognostic molecular profiling assays.
In conclusion, our results demonstrate that intrinsic imaging phenotypes of tumor
may heterogeneity exist, with independent and additional prognostic value in predicting
RFS. Additionally, these heterogeneity phenotypes show associations with established
histopathologic prognostic biomarkers, suggesting that image heterogeneity phenotypes
non-invasively capture underlying tumor biology.
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Chapter 4 : Longitudinal changes in spatial heterogeneity in dynamic
contrast enhanced-magnetic resonance imaging in response to breast
neoadjuvant chemotherapy
This work is under review.
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4.1. Introduction
Breast cancer heterogeneity is well-established, with intratumor heterogeneity
arising due to genomic and transcriptomic variations leading to heterogeneous
subpopulations driving prognosis and response to therapy4,11,39,170,171. As such, increased
heterogeneity is thought to be associated with adverse clinical outcomes6.
Neoadjuvant chemotherapy (NACT) is an established course of treatment for
locally advanced breast cancer (LABC) and can promote breast conserving surgeries by
reducing tumor size21. Additionally, women achieving pathologic complete response
(pCR) after completing neoadjuvant chemotherapy may have improved survival
outcomes172,173. Early prediction of response to neoadjuvant treatment can allow for
personalized changes to treatment plans, including targeted therapies, and early
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discontinuation of inactive therapies174,175. Intratumor heterogeneity is thought to change
in response to neoadjuvant chemotherapy, leading to altered biomarker expressions176.
Such changes may arise due to the acquired resistance of specific sub-clones during
treatment177. Early, noninvasive characterization of such changes may indicate response
versus resistance to treatment, enabling early treatment changes prior to treatment
completion.
Personalized gene expression based molecular assays, such as the 70-gene
MammaPrint microarray assay (Agendia BV) and the 50-gene PAM50 risk of recurrence
score assay (ROR-S), provide risk stratification for future recurrence178,179. p53 mutation
status is an established predictor for more aggressive tumor biology and therefore a worse
prognosis in terms of recurrence free survival (RFS)180. Such precision medicine
predictors may improve clinical decision making by deviating from the “one size fits all”
approach to treating breast cancer. However, as such assays, mutation statuses, and
established histopathologic biomarkers are determined largely from selective tissue
sampling acquired by biopsy, they may fall short in fully capturing heterogeneous disease
burden.
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) can allow
for longitudinal, non-invasive monitoring of heterogeneous tumors during the course of
neoadjuvant chemotherapy. Previous studies have demonstrated the role of longitudinal
patterns for tumor response during neoadjuvant chemotherapy and have examined their
associations with treatment response and overall survival69,104,181,182. Hylton et al.
demonstrated the prognostic and predictive value of measuring functional tumor volume
53

(FTV) at various longitudinal time points during neoadjuvant chemotherapy183. Jahani et
al. developed registration-based biomarkers for the early prediction of pCR and
recurrence free survival (RFS) in tumors from baseline to early treatment time points184.
While much progress has been made, these studies may be limited by not examining the
associations between aggregate changes in intratumor heterogeneity that arise in response
to therapy and the complementary information provided by genomics-based
information113.
The purpose of this study was to identify imaging phenotypes of early changes in
intratumor heterogeneity in DCE-MRI and evaluate their prognostic value in augmenting
FTV measures and molecular profiling signatures scores for predicting RFS after breast
NACT.

4.2. Discovery cohort
DCE-MR images of women enrolled in the ACRIN 6657/I-SPY 1 trial, diagnosed
with advanced invasive breast cancer from May 2002 through March 2006, were
retrospectively analyzed157,159. Per the inclusion criteria of ACRIN 6657/I-SPY 1, women
diagnosed with stage 2 or 3 breast cancer were selected for the study and underwent an
anthracycline-cyclophosphamide NACT. Longitudinal DCE-MRI was performed using a
1.5 T scanner at four time points: prior to the start of neoadjuvant therapy (T1), at least 2
weeks after the first cycle of chemotherapy (T2), between treatments (T3), and after the
completion of chemotherapy, before surgery (T4). Data acquisition was as described in
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the ACRIN 6657/I-SPY 1 protocol182. The first and second post-contrast images were
acquired 2.5 and 7.5 minutes after contrast injection.
Of the 222 trial participants with publicly available data157,159, we retained the 143
women for whom both complete clinical data and T1 and T2 DCE-MR imaging were
available. For analyses involving gene expression, we used the subset of 100 women for
whom gene expression information was available through the Gene Expression
Omnibus185,186, under the accession number GSE22226187. Clinical and histopathologic
data including age, hormone receptor (HR) status, human epidermal growth factor
receptor 2 (HER2) status, and pCR status were available for each woman. Functional
tumor volume at T2 (FTV2), previously shown to have significant association with
RFS183, was also calculated for each woman. RFS times were available, defined as time
to recurrence (event), or time to death or last follow-up (censor).

4.3. Validation cohort
A validation cohort of 92 women was formed from the remaining 43 women from
the original cohort (n=143) for whom gene expression data was not publicly available,
and a separate dataset of 49 women from the publicly available Breast MRI NACT Pilot
study

188

. This study had similar inclusion criteria as the I-SPY 1 trial, and participants

underwent a similar treatment and imaging protocol as the I-SPY 1 trial. Clinical
information on age, HR status, and HER2 status and 3-year RFS information was
available for each woman in the validation cohort.
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4.4. Approximation of gene expression based molecular profiling signatures
Molecular profiling of the I-SPY 1 enrolled women with gene expression
information was built as previously described189. Specifically, we re-created three gene
signatures in order to classify tumors regarding their metastatic potential, risk of
recurrence,

and

p53

oncogene

mutation

status:

the

70-gene

signature

(MammaPrint)190,191, PAM50 risk of recurrence (ROR-S)192,193, and p53 mutation
signature194, respectively. Briefly, MammaPrint classification was achieved by
calculating the cosine similarity of the expression of the 70-gene signature for each
sample against a “good prognosis” sample set190, using thresholds as defined in the
original study191. ROR-S sample categorization was determined by computing the
weighted sum of the correlation coefficients193 of each sample against the intrinsic
subtype sample sets of the PAM50 gene signature study192. Lastly, p53 mutation status
was estimated by calculating the proximity of the I-SPY 1 samples and the p53 mutation
signature centroids (wildtype vs. mutant) as Spearman’s correlation values, as described
in the p53 gene signature study194. The integrity of our classification was examined by
comparing our results with the original results of the Esserman et al. study187. We
confirmed that our recreated results corresponded to the original results by comparing the
numbers of individuals attributed to each class in the overall cohort.

4.5. Delta radiomic feature extraction
For each woman in the discovery cohort, the 3-D primary lesions at pre-treatment
(T1) and early-treatment (T2) time points were selected by first identifying the functional
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tumor volume (FTV) within the publicly available bounding region, as previously
reported158. The largest contiguous volume of voxels included in the FTV was selected as
the location for the primary lesion; this volume was then further refined using manual
segmentation to remove isolated voxels and include voxels within the primary tumor
lesion volume which were not initially selected by the FTV threshold158. Final tumor
segmentations for T1 and T2 were visually confirmed by a board-certified and fellowship
trained breast imaging radiologist (ESM). Images were preprocessed by N3 bias-field
normalization to correct for bias field signal161.
For each woman in the discovery cohort, at T1 and T2 time points, four voxelwise kinetic image maps were calculated within the segmented tumor, the peak
enhancement (PE) (Eq. 4.1), signal enhancement ratio (SER) (Eq. 4.2), wash-in slope
(WIS) (Eq. 4.3), and wash-out slope (WOS) (Eq. 4.4) images, to quantify the
enhancement patterns over the dynamic scans using the signal intensity for the precontrast, first post-contrast, and second post-contrast time points (

and

,

respectively).

Eq. 4.1

Eq. 4.2
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Eq. 4.3

Eq. 4.4

All kinetic image maps and tumor segmentations were resampled by linear
interpolation to a spatial resolution of 256 x 256 voxels, the lowest resolution of the data
cohort, to ensure consistent resolution across all scans. A total of 104 radiomic features
characterizing lesion intensity, texture patterns, and morphology were extracted from the
entire tumor region, from each kinetic map at each treatment time point, resulting in a
total of 416 features at each time point for each woman. All features were extracted using
the publicly available Cancer Imaging Phenomics Toolkit (CaPTk; v.1.7.1; University of
Pennsylvania; https://cbica.github.io/CaPTk/)163. Features at each treatment time point
(fT1 and fT2) were subsequently sign-adjusted such that increasing feature values
corresponded to increasing lesion heterogeneity as per each feature’s definition.
Subsequently, the change in each radiomic feature between the baseline and early
treatment time points, or delta feature Δf, was calculated as:

Eq. 4.5

These delta features were subsequently z-score normalized and features with
extreme skewness or low interquartile range (i.e., skewness>5, IQR<1) were excluded
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from further analysis. Features characterizing tumor texture or morphology in only 2-D
image dimensions were also excluded to allow for a whole-tumor, 3-D analysis. This
resulted in a total of 42 delta features included in our final analysis. To reduce
dimensionality and identify correlated delta features, features were clustered in an
agglomerative hierarchical manner using Pearson’s correlation as the distance metric,
with highly correlated features being grouped together. Consensus clustering was used to
determine the optimal number of stable delta feature groups, with each feature group
consisting of highly correlated delta features. Within each feature group, principal
component analysis (PCA) was performed and principal components (PCs) totaling
greater than 85% explained variance were retained to represent each feature group195. As
higher values for each delta radiomic feature prior to PCA indicated increasing
heterogeneity from T1 to T2, higher values of a PC incorporating primarily positive
contributions of features were interpreted as increasing heterogeneity, and one with
negative contributions were interpreted as decreasing heterogeneity196. The PCs found,
and their subsequent use in identifying imaging phenotypes of tumors, could serve to
characterize tumors as having radiomic signatures indicating increasing or decreasing
heterogeneity.

4.6. Identifying imaging phenotypes of early change in tumor heterogeneity
To identify imaging phenotypes of early changes in tumor heterogeneity, tumors
in the discovery cohort were classified via unsupervised hierarchical clustering, using the
retained principal components to represent each tumor. The clusters identified through
unsupervised clustering were interpreted as phenotypes of changes in heterogeneity seen
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in the study population. An overview schematic for how imaging phenotypes were
generated can be found in Figure 4.1. An agglomerative hierarchical approach was used
to cluster tumors, using Euclidean distance as the distance metric between the retained
principal components for each tumor. Ward’s minimum variance method was used as the
clustering metric165. To determine the optimal k number of clusters, consensus
clustering166 was used to determine the number of stable phenotypes by repeatedly
subsampling the data, performing unsupervised hierarchical clustering, and noting the
proportion of subsamples in which every pair of tumors occupied the same cluster when
they appeared in the same dataset. As such, a cumulative distribution function (CDF) was
determined for each increase in k, and the stable number of clusters was determined to be
the k at which the area under the CDF increased less than 10%. SigClust167 methods were
used to determine the number of significant phenotypes by calculating the significance of
the cluster index, a metric defined as the sum of within cluster sum of squares about the
overall mean, tested against a null distribution at each cluster division. The significance
of each phenotype split was tested at p < 0.05 (Figure 4.1).
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Figure 4.1. Identification of change in heterogeneity phenotypes. Primary lesion volume segmented from
pre-treatment (T1) and early-treatment (T2) DCE-MRI images (A). Four voxel wise kinetic image maps are
created for peak enhancement (PE), signal enhancement ratio (SER), wash-in slope (WIS), and wash-out
slope (WOS) images to quantify enhancement patterns over each dynamic scan from T1 and T2 images
(B). Radiomic features are extracted from each kinetic image map from both T1 and T2 images (C). Delta
radiomic features are calculated for each extracted feature (D). Delta radiomic features are clustered based
on correlation, and consensus clustering is used to determine the optimal number of stable feature clusters
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(E). Within each feature cluster, PCA is performed and the number of principal components is selected to
account for >85% of explained variance (F). Selected principal components are concatenated across all
feature clusters to form the final feature vector for each woman. Unsupervised hierarchical clustering of the
final feature vectors is performed to identify imaging phenotypes seen in the study population (G).

4.7. Prognostic value of early change in heterogeneity phenotypes-statistical
analysis
Distributions of clinical and histopathologic covariate values and molecular
profiling scores were assessed for differences across radiomic phenotypes using Chisquare and Kruskal-Wallis tests for categorical and continuous covariates, respectively.
Statistical corrections for multiplicity were made using the Bonferroni correction197.
RFS times across phenotypes were evaluated using Kaplan-Meier survival curves,
in both the whole cohort and within strata of HR status, HER2 status, TN status, and
greater than and less than median FTV2 values, with the log rank test used to determine
statistical significance. RFS was also modeled via Cox proportional-hazards regression.
Eight models were evaluated: univariable models for each molecular signature; the
baseline model — using the covariates age, HR status, and HER2 status; baseline +
FTV2; baseline + FTV2 + radiomic phenotype; and baseline + FTV2 + all molecular
signatures, both with and without the addition of radiomic phenotype. All models were
evaluated using 5-fold cross validation and averaged over 100 replicates.
The prognostic value of radiomic phenotypes was further evaluated by generating
a risk score for each woman, defined as the prediction score of covariates weighted by the
corresponding Cox-proportional hazard’s coefficients. Kaplan-Meier survival was
analyzed split on the median risk calculated by the Cox model using baseline factors and
FTV2.
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Lastly, confusion matrices for the categories of RFS event/censor were generated
to assess the predictive performance of radiomic phenotypes compared to MammaPrint
scores, ROR-s, and p53 mutation status.

4.8. Validation of early change in heterogeneity phenotypes
Tumor segmentations for cases in the validation cohort were generated similarly
to those in the discovery cohort. Delta radiomic features were calculated using the same
feature preprocessing methods used in the discovery cohort. The same delta features
selected in the discovery cohort were also selected for the validation cohort. These
resulting delta features were normalized using the mean and standard deviation values
from the delta feature values in the discovery cohort to standardize feature ranges.
Features were subsequently grouped together based on the cluster assignment of
correlated features determined from the discovery cohort. Within each validation feature
cluster, features were projected into the discovery cohort feature groups’ principal
component space to determine component values. The same numbers of PCs
summarizing each feature group retained in the discovery cohort were selected from the
validation cohort to form the validation cohort principal-component vectors.
To determine phenotype assignment in the validation cohort, each tumor was
assigned to the discovery cohort-identified phenotypes by minimizing the Euclidean
distance between each validation cohort principal component vector and the discovery
cohort phenotype centroid, defined as the average of the principal component vectors
across all tumors in each phenotype.
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4.9. Results
4.9.1. Discovery cohort
A total of 28 (28%) women included in the discovery cohort had future events of
recurrence while 72 (72%) women did not have future events of recurrence (Table 4.1).
Median RFS time was 3.9 years (range, 0.5–6.9 years)158. Neoadjuvant and radiation
therapy information was available for women in the discovery cohort (Table 4.2).
Table 4.1 Selected patient characteristics for discovery cohort.
No future event of
recurrence (n=72)

Future event of
recurrence (n=28)

Hormone Receptor
positive

28 (53%)

17 (61%)

HER2+ positive

23 (32%)

11 (39%)

pCR

23 (32%)

4 (14%)

Age (min-max)

48.15 (33.1864.33)

46.31 (28.7665.39)
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Table 4.2. Selected treatment characteristics for discovery cohort.
Locally advanced cancers (n=100)
No future event
of recurrence
(n=72)

Future event
of recurrence
(n=28)

Neoadjuvant Chemotherapy

p-value

> 0.99

Anthracycline-Cyclophosphamide
(AC) only

1(1.4%)

0 (0%)

AC + Tamoxifen

62 (86%)

24 (86%)

AC + Tamoxifen + Herceptin

8 (11%)

3 (11%)

AC + Tamoxifen + Other

1 (1.4%)

1 (4%)

Herceptin

8 (11%)

3 (11%)

> 0.99

Radiation Therapy

58 (81%)

19 (68%)

0.21

4.9.2Validation cohort
Of the women included in the validation cohort, 27 (29%) women had future
events of recurrence while 65 (71%) did not (Table 4.3). Median RFS time was 4.13
years (range, 0.28-8.79 years).
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Table 4.3. Selected patient characteristics for validation cohort.
No future event
of recurrence
(n=65)

Future event of
recurrence
(n=27)

Hormone Receptor positive

37 (57%)

10 (37%)

HER2+ positive

19 (29%)

10 (37%)

pCR

16 (25%)

4 (15%)

Min. age

27.85

31.01

Max. age

71.47

63.8

Mean age

48.58

46.18

4.9.3. Gene expression signatures classification
Recreated classifications closely approximated the original results, considering
minor differences regarding the sample cohorts (Appendix Tables B1-B3). Following
that, gene expression data were matched to the available imaging data for each patient.
The recreated methods were then utilized to classify each tumor in the discovery cohort.
Classifications are shown in Table 4.4. Further details regarding the recreated analysis are
available in Appendix B.

66

Table 4.4. Molecular profiles in the discovery cohort.
Gene
signature

Distribution rates (n = 100)

MammaPrint

13 (low risk)

87 (high risk)

p53 score

37 wildtype)

63 (mutant)

PAM 50
ROR-S

32 (low risk)

31 (int. risk)

37 (high risk)

4.9.4. Delta radiomic feature extraction
Four stable groups of correlated features were determined by consensus
clustering. Selecting the PCs totaling greater than 85% explained variance from each
group, a total of six principal components were identified to summarize change in
heterogeneity for each primary lesion.

4.9.5. Imaging phenotypes of early change in tumor heterogeneity
Two radiomic phenotypes of early change in intratumor heterogeneity were
identified using unsupervised hierarchical clustering and shown to be statistically
significant using the SigClust method (p<0.01). Comparing the average of the six
radiomic PC values observed for tumors in each phenotype allowed the two phenotypes
to be interpreted as decreasing (Phenotype 1, n=58) and increasing (Phenotype 2, n=42)
intratumor heterogeneity from T1 to T2 (Figure 4.2). A Bonferroni statistical correction
resulted in a p-value of less than or equal to 0.007 to signify statistical significance in
clinical covariate distribution across phenotypes. The number of future recurrences was
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significantly different across phenotypes (p < 0.001), with proportionally more
recurrences in Phenotype 2 (increasing heterogeneity) than Phenotype 1 (decreasing
heterogeneity), via the Chi-square test. Other clinical and histopathologic covariates, and
molecular signatures, were not significantly different across phenotypes (Figure 4.3).
Additionally, neoadjuvant treatment paradigms and targeted treatment paradigms were
not significantly associated with radiomic phenotypes. Kaplan Meier RFS curves were
also significantly different between phenotypes (p < 0.001).
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Figure 4.2. Unsupervised hierarchical clustering of tumors in the discovery cohort identified two
phenotypes of early changes in intratumor heterogeneity: decreasing heterogeneity from T1 to T2
(Phenotype 1, in blue) and increasing heterogeneity from T1 to T2 (Phenotype 2, in red) (A). Kaplan-Meier
curves for RFS of patient groups split by phenotype show significant separation, with tumors showing
increase in intratumor heterogeneity after initiation of neoadjuvant therapy (Phenotype 2) having worse
recurrence outcomes (B).
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Figure 4.3. Distribution of molecular profiling scores across phenotypes. Significant distributions across
the phenotypes were not seen in the three molecular profiling scores.

Within molecular subtypes of breast cancer, splitting women by radiomic
phenotype assignment showed no significant difference in RFS for the HR+/HER2subgroup (p = 0.3) and significant differences within the HER2+ and Triple Negative
subtypes (both p = 0.02) (Figure 4.4).

Figure 4.4. Kaplan Meier RFS curves split by phenotype assignment for (A) HR+/HER2-, (B) HER2+ and
(C) Triple Negative molecular subtypes of breast cancer in the discovery cohort.
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Kaplan Meier RFS curve separation by phenotype, within strata of FTV2 value
(less than/greater than median FTV2) also demonstrated significant differences; curve
separation on FTV2 itself was not significant (Figure 4.5).

Figure 4.5. Kaplan Meier RFS curves for the discovery cohort split by median FTV2 value (A) versus split
by phenotype within strata of less than median FTV2 (B) and greater than median FTV2 (C). RFS split by
above/below median FTV2 does not show p < 0.05 for separation. Within each stratum of FTV 2, the split on
phenotype is significant (B and C).

Kaplan-Meier curve separation of tumors split on the median risk score generated
from a Cox proportional hazards model using baseline model covariates (age, HR status,
and HER2 status) and FTV2 was significant (p=0.04). Within the low-risk tumors, further
separation on phenotype demonstrated no significant curve differences. For high-risk
tumors, separation by phenotype was significant (p < 0.01) (Figure 4.6).
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Figure 4.6. Survival versus risk score for the discovery cohort calculated by a Cox model using baseline
model covariates (age, HR status, and HER2 status) and FTV2. Split on above versus below median risk
(A). Split on phenotype within the low-risk stratum (B). Split on phenotype within the high-risk stratum
(C).

Univariable Cox regression models based on each of MammaPrint, ROR-S, and
p53 scores resulted in c-statistics of 0.64, 0.64, and 0.66, respectively. Kaplan Meier
survival curves for MammaPrint, ROR-S, and p53 scores were not significant (Figure
4.7).

Figure 4.7. Kaplan Meier survival curve for molecular profiling scores.

A baseline model (model 1) based on age, HR status and HER2 status resulted in
a cross validated, averaged over 100 replicates, c-statistic of 0.55. Adding FTV2 to the
baseline model (model 2) improved the c-statistic to 0.67 and adding molecular
signatures to the baseline and FTV2 model (model 3) resulted in a c-statistic of 0.61. A
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model of baseline, FTV2, and radiomic phenotype assignment (model 4) resulted in a cstatistic of 0.73 and a combined model of baseline, FTV2, molecular profile scores, and
radiomic phenotype assignment (model 5) demonstrated improved discriminatory
capacity with a c-statistic of 0.79. The improvement in the final combined model was
significant compared to the baseline, FTV2, and molecular signature score model, as
determined by the log-likelihood test (p<0.01) (Table 4.5).
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Table 4.5. Univariable and multivariable Cox models of RFS within the discovery
cohort.
c-statistic

95% CI
for cstatistic

Model p1

MammaPrint

0.61

0.59-0.63

0.2

ROR-S

0.64

0.63-066

0.1

p53 score

0.58

0.56-0.60

0.06

Model 1: Baseline
(age, HR status,
HER2 status)

0.55

0.55-0.56

0.7

Model 2: Baseline,
FTV2

0.67

0.66-0.68

0.06

0.0052

Model 3: Baseline,
FTV2, molecular
signatures

0.61

0.59-0.62

<0.05

0.133

Model 4: Baseline,
FTV2, phenotype

0.73

0.72-0.74

< 0.01

0.013

Model 5: Baseline,
FTV2, molecular
signatures, phenotype

0.79

0.78-0.81

<0.001

0.0024

Model

p
versus
nested
model

1. p versus null model of equal hazard for all patients.
2. p versus Model 1, log-likelihood test.
3. p versus Model 2, log-likelihood test.
4. p versus Model 3, log-likelihood test.

Confusion matrices for associations between molecular profile scores and
radiomic phenotypes and RFS event/censor were generated. Overall positive predictive
values (PPV) and negative predictive values (NPV) for MammaPrint, ROR-S, p53
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mutation status and radiomic phenotype assignment demonstrated that radiomic
phenotype status had the highest PPV and NPV out of the four models (Figure 4.8).

Figure 4.8. Confusion matrices for RFS prediction models within the discovery cohort using MammaPrint
score (A), ROR-S (B), p53 mutation status (C), and radiomic phenotype (D).

The two radiomic phenotypes identified in the discovery set were replicated in the
validation cohort and found to be statistically significant via the SigClust method
(p=0.04). Kaplan-Meier curves of tumors in the validation cohort split by phenotype also
had a statistically significant difference (p<0.01). A Bonferroni statistical correction
resulted in a p-value of 0.008 to mean statistical significance in clinical covariate
distribution across phenotypes. The proportional number of recurrences was significantly
different across phenotypes (p=0.004) using the Chi-square test, with Phenotype 2
(increasing heterogeneity) having proportionally more recurrence evens than Phenotype 1
(decreasing heterogeneity) (Figure 4.9).
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Figure 4.9. Replication of radiomics phenotypes in the validation cohort found to be significant (p=0.04)
(A). Kaplan-Meier curves for RFS split on radiomic phenotype show significant separation (p = 0.002) (B).
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4.10. Discussion
Two intrinsic radiomic phenotypes of early change in intratumor heterogeneity in
response to neoadjuvant chemotherapy for locally advanced breast cancer were identified
and validated. Interpretation of the two radiomic phenotypes as capturing an increase and
decrease in intratumor heterogeneity from pre-treatment to early-treatment showed that
tumors assigned to the phenotype with increasing intratumor heterogeneity had a greater
number of future recurrences. This was further supported by significant separation in
Kaplan Meier curves when stratifying women by phenotype assignment. Additionally,
the stratification of women within FTV subgroups by phenotype demonstrates the added
value of radiomic analysis in modeling prognosis (Figure 4.5). Augmenting established
clinical and histopathological prognostic factors with molecular signature scores and
radiomic phenotypes resulted in better prediction of RFS. This suggests that leveraging
the complementary information provided by genomic and radiomic data can allow for a
more comprehensive assessment of tumors and personalized therapy selection.
There may be certain plausible explanations for our observations. By capturing
changes in kinetic maps of the DCE-MRI data, the identified phenotypes could reflect
changes in tumor composition and angiogenic properties in response to neoadjuvant
chemotherapy. Increased heterogeneity may in turn reflect tumor plasticity, which can
lead to acquired resistance. The imaging phenotype demonstrating increased
heterogeneity from baseline to early-treatment exhibited an increased number of
recurrence events, thus supporting the hypothesis that more heterogeneous tumors may
result in more adverse clinical outcomes. In contrast, the radiomic phenotype
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demonstrating decreasing heterogeneity from pre-treatment to early-treatment included a
higher number of tumors achieving pCR, which may suggest a relationship between
decreased intratumor heterogeneity and an improved response to neoadjuvant
chemotherapy (Figure 4.2).
Interpreting the radiomic phenotypes of change in tumor heterogeneity through
the lens of tumor biology may provide further insight into the biologic changes occurring
within the tumor in response to neoadjuvant chemotherapy. As an example, two
representative tumors from women with similar age, receptor status, FTV2 values, and
ROR-S scores indicating low risk of recurrence were assigned to separate imaging
phenotypes based on their early change in heterogeneity. The tumor assigned to
Phenotype 2, with an increase in intratumor heterogeneity after initiation of treatment,
actually had a future event of recurrence while the tumor assigned to Phenotype 1, having
a decrease in intratumor heterogeneity, did not have a future event of recurrence (Figure
4.10). For these two representative cases, both women were of similar age with similar
histopathologic status (HR+/HER2-). While ROR-S scores for both women characterized
their tumors as “low risk of recurrence”, the women had different MammaPrint and p53
status and were assigned to separate phenotypes based on their early change in their
intratumor heterogeneity. In this particular example, the woman classified as “high risk”
by MammaPrint score, went on to have no future recurrence event, while the woman
classified as “low risk” did have a future event of recurrence. As MammaPrint status and
p53 status assignments were not significantly associated with phenotype assignment
across the cohort (Figure 4.3), this suggests that the complementary information provided
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by radiomic and genomic analysis could allow for increased confidence in treatment
planning and clinical decision making. Furthermore, examining the principal component
feature values for each woman suggests that quantitative imaging characterizations could
reflect differences in these two tumors that may predict future outcomes. Of the six
principal components used to cluster all tumors into the two phenotypes, C1-PC1, C4PC1, and C3-PC1 distributions were found to be statistically significant tested against a
p-value of 0.05 using Significance Analysis of Microarrays Test198. Examining the delta
radiomics features comprising each feature cluster from which the principal components
were generated could provide more insight into the specific quantitative differences in
tumors in each phenotype. Specifically, as all radiomic features were extracted from the
voxel-wise kinetic images, they provide a quantitative characterization of tumor
angiogenesis and perfusion related properties. C1-PC1 consists largely of features
characterizing changes in tumor morphology across all kinetic images, including ellipse
diameter and sphericity. In the representative images, the tumor assigned to Phenotype 2
has a greater value of this feature, suggesting that it had an increase in ellipse diameter
and more irregular volume moving from T1 to T2. C4-PC1 consists of features
characterizing changes in mean contrast intensity, specifically from the WOS image. As
this image quantifies the rate of “wash-out” of contrast agent, the representative image in
Phenotype 2 may have an increase in tumor wash-out from T1 to T2, suggesting an
increase in leaky vasculature due to increased angiogenesis, a characteristic of more
aggressive tumors199. Lastly, C3-PC1 consists of features summarizing morphologic
flatness across all four kinetic images. Both representative tumors have similar values for
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this feature suggesting that both tumors decreased in morphologic flatness from T1 to T2
(Table 4.6).

Figure 4.10. Representative tumors from Phenotype 1 (early decrease in intratumor heterogeneity) and.
Phenotype 2 (early increase in intratumor heterogeneity) shown in DCE-MRI scans at T1 and T2 from the
discovery cohort. (A) Representative 2D DCE-MRI slice and tumor region for T1 and T2 images from a
woman, age 50, with an HR+/HER2-, ROR-S low risk, p53 wildtype (low risk), and MammaPrint score of
-0.18 (high risk) tumor with no pCR and no future event of recurrence assigned to Phenotype 1. (B)
Representative 2D DCE-MRI slice and tumor region for T1 and T2 images from a woman aged 42, with an
HR+/HER2-, low risk ROR-S, p53 mutant (high risk), and MammaPrint score of -0.41 (low risk) tumor
with no pCR and a future event of recurrence assigned to Phenotype 2. (C) Representative 2D images of
PE, SER, WIS, and WOS voxel-wise maps for T1 and T2 for the tumor in phenotype 1. (D) FTV at T2
overlay for these representative tumors from phenotype 1 and 2. (E) Representative 2D images of PE, SER,
WIS, and WOS voxel-wise maps for T1 and T2 for the tumor in phenotype 2. (F) FTV at T2 values for
each representative tumor. Values for features (G) C1-PC1, (H) C4-PC1, and (I) C3-PC1, for each
representative tumor. These representative cases provide an example where imaging characterizations of
changes in each tumor’s heterogeneity provided a stratification related to future outcomes. In this example,
established clinical covariates did not provide such stratification.
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Table 4.6. Radiomic features comprising significant feature cluster principal
components.
Cluster 1- PC1

Cluster 4- PC1

Cluster 3- PC1

PE Intensity Quartile Coefficient of Variation

WOS Histogram Ninetieth Percentile

PE Morphologic Flatness

PE Morphologic Ellipse Diameter Axis 0

WOS Histogram Root Mean Square

SER Intensity Interquartile Range

PE Morphologic Ellipse Diameter Axis 1

WOS GLCM Entropy

SER Morphologic Flatness

PE Morphologic Ellipse Diameter Axis 2

WOS GLRM Short Run High Grey Level
Emphasis

WIS Morphologic Flatness

PE Morphologic Equivalent Spherical Radius

WOS GLSZM Grey Level Mean

WOS Morphologic Flatness

SER Morphologic Ellipse Diameter Axis 0
SER Morphologic Ellipse Diameter Axis 1
SER Morphologic Ellipse Diameter Axis 2
SER Morphologic
Radius
WIS Intensity
Variation

Equivalent

Quartile

Spherical

Coefficient

of

WIS Morphologic Ellipse Diameter Axis 0
WIS Morphologic Ellipse Diameter Axis 1
WIS Morphologic Ellipse Diameter Axis 2
WIS Morphologic
Radius

Equivalent

Spherical

WOS Morphologic Ellipse Diameter Axis 0
WOS Morphologic Ellipse Diameter Axis 1
WOS Morphologic Ellipse Diameter Axis 2
WOS Morphologic
Radius

Equivalent

Spherical

WOS GLSZM Zone Size Nonuniformity

Significant separation of women by radiomic phenotype assignment by Kaplan-Meier
curves for women with HER2+ and triple-negative breast cancers may further highlight
the known sub-clonal diversity within these subtypes (Figure 4.4)200-202. Our findings
suggest that tumors within these subgroups that become more heterogeneous as an early
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response to neoadjuvant chemotherapy may be more aggressive, resulting in increased
likelihood of recurrence.
Confusion matrices for RFS prediction using molecular signatures and radiomic
phenotype assignment demonstrate a greater PPV and NPV when using radiomic
phenotypes (Figure 4.8). However, a limitation of using only radiomic phenotypes can be
seen when comparing the predictive value of radiomic phenotypes alone against the
MammaPrint assay. Seven women in Phenotype 1 went on to have recurrence despite
decreasing heterogeneity on imaging whereas only 2 women, identified as a MammaPrint
“low risk”, had a recurrence. Leveraging the complementary information from both
personalized molecular signatures and incorporating longitudinal data about tumor
heterogeneity resulted in the most accurate predictive model in our study.
Limitations to our study should be noted. First, our exploratory analysis included
a relatively small sample size, as we restricted it to publicly available data from the
ACRIN 6657/I-SPY 1 trial with both DCE-MRI and gene expression data available. In
addition, the validation cohort utilized for this study did not include gene expression data
which prevented us from validating the prognostic benefit of the molecular profiling
scores. The publicly available microarray data used to generate the molecular profiling
scores was also limited by older acquisition protocols and technology. Additionally,
image analysis was limited by the older image acquisition protocol and technology used
in this study. However, the scan duration used for the dataset deriving from the I-SPY 1
trial was 4.5 minutes, which is similar to the current American College of Radiology
(ACR) recommendation of <= 4 minutes203. Moreover, the datasets used in this study for
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discovery and validation are among the only publicly available datasets with true longterm follow up available following NAC. Ultimately, given the encouraging, exploratory,
and proof of concept results with these older MRI protocols, we can hypothesize that the
performance of the proposed radiomic features may be better with newer MRI protocols.
Future work will include expanding our analysis to larger cohort sizes with images
acquired with newer, more clinically utilized MRI acquisition protocols, as well as
exploring relationships between early changes in tumor heterogeneity via radiomic
phenotyping and differentially expressed genes with related molecular pathways.
Additionally, utilization of Next Generation Sequencing (NGS) techniques which, in
contrast with microarrays, do not depend on specific probes for the quantification of the
expression of pre-specified genes, will allow for deeper analyses.
In conclusion, our exploratory results demonstrate that early changes in
intratumor heterogeneity in response to neoadjuvant chemotherapy as captured by
radiomic analysis of DCE-MRI may provide improved prediction of RFS for locally
advanced breast cancer. Longitudinal non-invasive assessment of tumor phenotypes via
imaging may allow for monitoring of heterogeneity and underlying tumor biology.
Augmenting clinical, histopathologic, and molecular covariates with imaging phenotypes
may allow for personalized risk stratification and early adaptation of treatment strategies.
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Chapter 5 : Developing a 4-D segmentation method to characterize
intratumor heterogeneity
5.1. Introduction
Given the current hypotheses of linear and branched evolution for breast tumor
progression, sub-clonal populations are thought to be spatially contiguous regions of
shared physiologic function. Partial volume effects introduced during medical image
reconstructions result in an image blurring effect, caused by the finite spatial resolution of
an imaging system following a 3D convolutional operation of the source with a point
spread function204. Additionally, voxel sampling as a 3-D grid suggests that neighboring
voxels may share underlying tissue structure, or that a single voxel may summarize the
signal of multiple tissue structures, a phenomenon known as the “tissue fraction
effect”204. As such, it is hypothesized that imaging representations of intratumor
heterogeneity would result in spatially contiguous voxels sharing similar physiological
behavior.
Conventional radiomic features largely aim to quantify the spatial distribution of
voxel intensities28. While informative when paired with imaging modalities with high
spatial resolutions, some imaging modalities, such as PET, may be limited in spatial
resolution. Instead, novel methods to characterize intratumor heterogeneity by leveraging
the molecular specificity provided by PET imaging should be leveraged.
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Preliminary

work

suggests

that

established

unsupervised

parcellation

techniques205 are inadequate for identifying spatially constrained, functionally similar
sub-regions. Such methods (e.g. k-means clustering, hierarchical clustering) assume that
dynamic data extracted from each voxel is independent from its surrounding voxels.
While many segmentation techniques exist, a novel paradigm is required to perform an
unsupervised segmentation of spatially constrained, non-rigid, and arbitrarily shaped
regions with discrete functional behavior. Other established segmentation techniques are
designed for segmenting well defined anatomical structures or require manual
initialization or well-defined control points206-208. Probability based clustering methods209
require an user-defined threshold for segmentation and therefore may not account for
partial volume effects204. We hypothesize that a segmentation method incorporating both
spatial and temporal image information would have improved segmentation accuracy
over established methods utilizing only temporal dynamics or spatial information alone.
Incorporation of spatial constraints to a segmentation method may account for tissue
fraction and partial volume effect
We have developed a method to characterize 4-D functional tumor heterogeneity
(FTH) by aiming to capture aspects of both spatial and kinetic tumor heterogeneity as
seen in dynamic imaging. Identifying functionally discrete sub-regions within a single
tumor region may allow for characterizing the extent of intratumor heterogeneity and
may lead to studies monitoring sub-region growth and response to treatment. Leveraging
the improved dynamic sampling and molecular specificity afforded by dynamic PET
imaging may allow for non-invasive, novel prognostic and predictive markers to
85

characterize tumor molecular biology. The developed method is agnostic to the specific
radiotracer utilized and does not depend on complex kinetic modeling assumptions.
Instead, the approach is data driven in terms of identifying intrinsic 4-D patterns of
molecular tumor heterogeneity.

5.2. Simulated image phantoms
Algorithm development and training was carried out using simulated 4-D PET
data. With the goal of developing a method with broad applicability, agnostic to
radiotracer or disease site, we chose to perform these algorithm trainings using a tracer
with broadly similar tracer kinetics to fluorodeoxyglucose (18F-FDG) (FDG), a
commonly used radiotracer in cancer staging. Simulated dynamic PET images based on
data from fluorothymidine (18F-FLT) (FLT) PET210 were utilized for method
development and validation. FLT was chosen as a representative tracer with kinetics
similar to other trapped cancer-relevant radiotracers to assess the generalizability of our
method. All simulations were done using Geant4 Application for Tomographic Emission
(GATE)211. The scanner simulations were based on the PennPET Explorer212 with 70-cm
axial field of view. Based on prior human studies of FLT data from patients with lung
cancer210, kinetic parameters were selected to emulate low, medium, and high KFLT
lesions (ml/cm3/sec) and the blood input curve was derived from an FLT PET patient
dataset and fit to a tri-exponential model. Details on simulated image generation have
been previously described213. The simulated images were cropped to a region-of-interest
(ROI) comprising the simulated regions and surround background area to a total size of
64x69x9 voxels x 45 frames. The simulated images consisted of two regions modeling
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low tracer uptake (10mm and 13mm sphere diameter), two regions modeling medium
tracer uptake (10mm and 13mm sphere diameter), two regions modeling high tracer
uptake (10mm and 13mm sphere diameter), a blood region, and a background region
(Figure 5.1).

Figure 5.1. Dynamic FLT-PET simulation images used for method development and validation. (A) Input
data used to generate dynamic simulations. (B) Labels for all regions in simulated image. (C) Center slice
images from representative simulation frames. (D) Average TACs for simulation sphere and blood curve
regions.

5.3. Limitations of existing methods

Unsupervised segmentation analysis allows for the intrinsic grouping of 4-D
functional data without prior knowledge of voxel labels. Mapping histopathologic ground
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truth to imaging representations of sub-clonal regions is often limited by the nonisotropic resolution of voxels and tissue deformation that can occur between resection
and fixation for histology analysis7,21.
Developing a method to identify functionally discrete sub-regions began by
evaluating the performance of established unsupervised clustering algorithms for time
activity clustering and by adding spatial constraints to these established methods. Use of
the simulated image phantoms allowed for evaluating method performance when
segmenting spatially constrained, functionally discrete sub-regions. Initial method
performance was evaluated using visual inspection of the resulting segmentation of
simulated spheres image, allowing for iterative improvements to be made.
The first evaluated unsupervised technique was hierarchical clustering, grouping
together voxels within the image based on the Euclidean distance between time activity
curves. Ward’s method for minimum variance was used as the clustering criteria.
Qualitative assessment of the resulting segmentation suggested a need for adding a spatial
weight to ensure that minimum variations in time activity behavior within a region,
causing neighboring voxels to be classified with different labels, could be offset by
spatial proximity.
A spatially weighted clustering method for hierarchical clustering was then
implemented to promote within cluster minimization based on voxel spatial location and
functional behavior, as seen in Eq. 5.1.

88

Eq. 5.1

Here, df represents the within cluster Euclidean distance between time activity curves
between voxels i and j. Similarly, ds represents the within-cluster Euclidean distance
between spatial coordinates for voxels i and j. The term α is used to control the degree of
influence either functional similarity or spatial similarity has on the minimization. Use of
this minimization function was implemented with hierarchical clustering and assessed
qualitatively.
Next, dynamic time warping (DTW) was used instead of Euclidean distance, to
identify alignment between voxels’ time activity curve behaviors214. DTW is a technique
used to find the optimal alignment between two time-dependent sequences that have been
sampled at equidistant points in time. Briefly, the pairwise distance between time series,
X and Y, are first calculated. Within this, the algorithm aims to find and alignment path
through low-cost areas of the distance matrix215. The resulting segmentation performance
of using hierarchical clustering with DTW as a distance metric in the time domain was
assessed qualitatively.
Spectral clustering is a clustering algorithm utilizing graph-based segmentation
techniques. This algorithm calculates the distance between all voxels and then uses the
top eigenvectors of this distance matrix to form groupings. Briefly, an adjacency matrix
is created in which each element is the pairwise adjacency between two voxels, xi and xj,
defined as:
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Eq. 5.2

Here, df represents the within cluster Euclidean distance between time activity curves
Between voxels xi and xj. From this, a degree matrix, a diagonal matrix with degrees
d1,…,dn calculated along the diagonal is calculated as:
Eq. 5.3

For each voxel i, summing over all voxels adjacent to i. The non-normalized
Laplacian L, is then calculated as L= D- W. From this, the first k eigenvectors
summarizing L are calculated, and then k-means clustering is used to cluster the
eigenvectors into sub-groups216. Spectral clustering was used to segment the simulated
image with voxels represented as time activity curves, and segmentation performance
was qualitatively assessed.
A spatial constraint was then added to the spectral clustering adjacency matrix as
previously identified, by multiplication of an exponential spatial weight:
Eq. 5.4

where ds represents the within-cluster Euclidean distance between spatial coordinates for
voxels xi and xj. This exponential spatial weight was added to penalize clustering
assignment by spatial location, such that voxels grouped together according to functional
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data would also be spatially contiguous. Segmentation performance was qualitatively
assessed.
Lastly, wavelet decomposition analysis was explored to reduce the dimensionality
of time activity curves prior to clustering. The segmentation performance of representing
voxels by their first wavelet decomposition was qualitatively assessed. Representative
segmentations of the central 2-D slice of the simulated image phantoms from all
evaluated techniques can be seen in Figure 5.2. These evaluated methods did not
qualitatively result in successful segmentation of the simulated image.

Figure 5.2. Segmentation performance for various evaluated techniques applied to the simulated phantom
images. Segmentation performance was qualitatively assessed by visually comparing performance to the
true segmentation labels.
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Overall, these experiments suggested the need for improved representation of
similarities in time activity behavior along with a spatial weight in order to segment the
simulated images in 4-D.

5.4. Radiomic functional intratumor (Rad-FIT) clustering
Due to the limitations of existing unsupervised voxel parcellation methods and in
order to better assess both the spatial and temporal heterogeneity seen in breast tumors,
Radiomic Functional Intratumor (Rad-FIT) clustering was developed as a 4-Dsegmentation method to segment tumors into spatially constrained, functionally discrete
sub-regions (Table 5.1).
In

characterizing

intratumor

heterogeneity,

the

assumption

of

voxel

independence8, upheld in many conventional unsupervised clustering studies, does not
hold due to overwhelming evidence suggesting that neighboring voxels share physiologic
similarity39. Therefore, a method incorporating a voxel’s spatial neighborhood in its own
label assignment was incorporated. Further, Rad-FIT clustering does not require manual
initialization or defined control points. Instead, we utilized a randomly initiated k-means
clustering for initialization. Compared to other clustering algorithms that determine hard,
spherical or compact clusters (e.g. k-means clustering), or prevent adjustment once a
cluster merge or split decision has been executed (e.g. hierarchical clustering), Rad-FIT
clustering allows for an iterative, probability-based label assignment with no prior
assumption about sub-region shape. Lastly, Rad-FIT clustering allows for easier
interpretation of within sub-region similarities and between sub-region differences, as
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compared to other graph-based segmentation approaches, due to summarizing time
activity information into dominant modes of variation.
For a given voxel v within a 3-D ROI, the 4-D functional behavior can be
represented as v(x,y,z,y,t) given a 3-D spatial location x,y,z and t representing the temporal
signal from a set of dynamic frames. The temporal signal of an ROI over dynamic PET
scans is first summarized using functional principal component analysis (FPCA).
Functional principal component analysis (FPCA) is a method used to determine modes of
variation in functional data. Principal component analysis (PCA) is a well-established
method for dimensionality reduction and capturing dominant modes of variation in high
dimensional data through a set of orthonormal vectors. Similarly, FPCA extends this idea
to continuous functions in time, where the dominant modes of variation in the time
curves are represented as eigenfunctions, and data points are projected into this space
represented by functional principal components. Use of FPCA allows for the
dimensionality reduction of time series data for each voxel while retaining the variance of
its temporal information. The dynamic scan is then reduced, with each voxel represented
using functional principal components (FPC) capturing greater than 85% of the variance
seen in its dynamic behavior (vx, y, z, f).
A Markov Random Field (MRF) segmentation paradigm is applied to the voxel
data. Here, ignoring the independence assumption between image voxels, the prior
probability of a label z for pixel vx,y,z,f is then modeled using a simple state prior model
(Eq. 5.5) 217.
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Eq. 5.5

where k is the number of possible labels, β is a floating parameter controlling the
influence of neighboring voxels, and Nx,y,z defined as a 3x3x3 voxel grid surrounding
vx,y,z,f. The likelihood model of vx,y,z,f is modeled as a multivariate Gaussian distribution
(Eq 5.6).

Eq. 5.6

Initialization of mean and standard deviation values for each label k is performed using
K-means clustering with a predetermined number of k labels. The posterior distribution
for all labels, k, and all n pixels within the ROI is modeled by,

Eq. 5.7

and parameters

are updated by the following equations (Eq 5.8, Eq 5.9):
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Eq. 5.8

Eq. 5.9

where j is the number of FPCs selected. The optimization problem and parameter
estimation is then solved using the expectation maximization (EM) algorithm218.
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Table 5.1. Radiomic functional intratumor (Rad-FIT) clustering

Algorithm 1 — Radiomic functional intratumor (Rad-FIT) clustering
Input: Vi ∈ R3×t,

(floating parameter), k (number of sub-regions)

Output: z ∈ [0,1]K (Clustering Assignment)
Initialization: Initialize z,

by K-means clustering algorithm

Step 1: Functional principal component analysis (retain components with 85% of
variance:
V(x,y,z,t) » V(x,y,z,f)
Loop- Repeat (t) until convergence
• Fix z,
• Fix

— Solve for
—

• Solve for

5.5. Initialization of Rad-FIT clustering
K-means clustering was chosen as the initialization technique for Rad-FIT
clustering to determine an initial parameter estimation for the conditional distribution. Kmeans clustering is well established as an initialization method for probability-based
clustering using the EM algorithm. Use of k-means clustering as an initialization method
over random initialization resulted in improved performance of Rad-FIT clustering
(Figure 5.3).
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Figure 5.3. Comparison of initialization techniques. Segmentation performance of (A) K-means clustering
as an initialization method for (B) Rad-FIT clustering as compared to (C) random initialization as an
initialization method for (D) Rad-FIT clustering. Initialization approaches were evaluated for 2-class
segmentation, 3-class segmentation, and 5-class segmentation. Varying colors represent how the image has
been segmented into discrete classes.

5.6. Value of dynamic imaging versus static imaging
Previous studies have demonstrated the improved prognostic and predictive value
of utilizing dynamic PET imaging over static imaging22. However, static imaging is more
widely implemented in a clinical setting than a more conventional PET imaging
protocol219. To determine whether temporal sampling over a 60 min dynamic imaging
scan offered additional information to that from a static image, or an image with a subsampled number of temporal frames when identifying 4-D sub-regions, the performance
of Rad-FIT clustering was evaluated on the final frame of the 60-minute scan as well as
using the first, middle, and final frames over the 60-minute scan. (Figure 5.4). The
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resulting segmentation performances were qualitatively assessed and demonstrated the
additional information provided by leveraging the entire dynamic scan.

Figure 5.4. Rad-FIT clustering performance when only a static scan or a sub-sampled dynamic scan is
utilized. Qualitative assessment suggests the full dynamic scan offers information beyond that of a static or
sub-sampled scan required for more accurate segmentation performance. Varying gray scale colors
represent different classes each image has been segmented into.

5.7. Signal to noise ratio experiments
The floating parameter β used in the MRF-based prior probability in Rad-FIT
clustering controls the degree of influence a voxel’s spatial neighborhood has on its own
label assignment. In order to select the optimal value of β, we assessed an array of values
ranging from 0 to 3 to determine which resulted in the best segmentation performance
when used in Rad-FIT clustering. These values were selected empirically based on the
high degree of variation in clustering performance seen when using this range of β and
also based on prior studies demonstrating use of a spatial weight of similar value220. To
model the effects of spatial noise often seen in PET images due to variations in image
reconstruction techniques, we utilized images of the same simulated image phantom
reconstructed with one-half and one-quarter of the counts derived from simulated
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positron annihilation events to effectively model one-half or one-quarter of the
radiotracer signal, resulting in images with increased signal to noise ratio (SNR). For
these simulated images, the original 45 frames (full dose of 4.0 mCi (148 MBq), were
subsampled to roughly correspond to emulated doses of 2.0 mCi (74 MBq) for the onehalf simulation and 1.0 mCi (18.5 MBq) for the one-quarter simulation213. Use of the
varying SNR images also allowed us to evaluate the optimal value of β that would allow
for neighboring voxels of shared functionality to be grouped together independent of
image noise. The value of β (β =2.6) that resulted in the highest Dice score with minimal
variation across the three simulated image SNR conditions was selected as the optimal
value (Figure 5.5).

Figure 5.5. Optimal value of β across simulations of varying signal to noise ratio.
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5.8. Evaluating method performance on simulated image phantoms
To evaluate the performance of segmenting spatially contiguous regions of
heterogeneous tracer activity with Rad-FIT, the following segmentation assessments were
performed.
First, the improved value of summarizing temporal information from dynamic
voxel behavior using FPCs was evaluated. The segmentation performance of Rad-FIT
when simulation voxels were represented by their original time activity curves was
compared to the performance when simulation voxels were represented by their FPC
scores.
The segmentation performance of Rad-FIT was then evaluated for its ability to
segment the high, medium, and low uptake 13mm spheres from each sphere’s
surrounding background region, respectively. All segmentation performances were
compared against the performance of established unsupervised segmentation algorithms
including K-means clustering, hierarchical clustering, and spectral clustering216. K-means
clustering and hierarchical clustering are well-established unsupervised clustering
techniques used to find intrinsic groupings within data structures. As spectral clustering is
a graph-based segmentation method relying on the functional similarity and adjacency
between voxels to identify image partitions, it allowed for more equal comparisons in
segmentation performance.
Average signal to background ratios for the low, medium, and high uptake
spheres were 1.78, 6.95, and 11.89, respectively. When segmenting low, medium, and
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high uptake spheres from their surrounding background region, segmentation
performance for all segmentation methods improved when simulation voxels were
represented by the FPCs capturing greater than 85% of TAC variability as opposed to
using the TACs. Additionally, Rad-FIT clustering demonstrated the highest segmentation
performance when segmenting low, medium, and high uptake sphere regions from its
surrounding backgrounds when evaluated using the Dice score221 (Table 5.2) and Jaccard
index (Table 5.3). Both the Dice score and Jaccard index are established statistical
metrics used to determine the degree of overlap between the true regions and resulting
regions from the segmentation algorithm. Both Dice scores and Jaccard indices include
values ranging from 0 to 1, with a value of 1 indicating perfect similarity between true
and segmented regions. Segmentation performance of each algorithm on a representative
center slice (2-D) for the high sphere region (Figure 5.6), medium sphere region (Figure
5.7), and low sphere region (Figure 5.8) can be seen below.
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Table 5.2. Average segmentation performance over ten replicates evaluated using the Dice scores
when segmenting low, medium, and high uptake simulated sphere regions from surrounding
backgrounds. Standard deviation in parentheses.

Dice scores
Segmentation
region
Low uptake
sphere

Medium
uptake sphere

High uptake
sphere

Hierarchical Spectral
Voxel
clustering
representation clustering
Time activity
0.15 (0)
0.04 (0.001)
curves
FPC

0.67 (0)

0.16 (0.03)

Time activity
curves

0.77
(<0.001)

0.06 (0.01)

FPC

0.78 (0)

0.20 (0.18)

Time activity
curves

0.72 (0)

0.18 (0.07)

FPC

0.83 (0)

0.17 (0.03)
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K-means
clustering
0.13
(0.06)
0.65
(0.02)

Rad-FIT
clustering

0.44 (0.4)

0.73(< .001)

0.84
(0.03)
0.52
(0.40)
0.84 (0)

0.24 (0.07)
0.70 (0.01)

0.85 (0)
0.66 (0)
0.86 (0)

Table 5.3. Average segmentation performance over ten replicates evaluated using the
Jaccard index when segmenting low, medium, and high uptake simulated sphere regions
from surrounding backgrounds. Standard deviation in parentheses.

Jaccard indices
Segmentation
Voxel
Hierarchical Spectral
K-means Rad-FIT
region
representation clustering
clustering clustering clustering
Time activity
0.07
0.08 (0)
0.01 (0.01)
0.14(0.05)
Low uptake
curves
(0.03)
sphere
FPC
0.50 (0)
0.09 (0.03) 0.55 (0.2)
0.54 (0)
Time activity
0.30
0.64 (0)
0.015(0.02)
0.58 (0)
curves
(0.37)
Medium
uptake sphere
0.72
0.74
FPC
0.65 (0)
0.12 (0.17)
(0.04)
(< .01)
Time activity
0.44
0.56 (0)
0.52 (0.04)
0.52 (0)
High uptake
curves
(0.36)
sphere
FPC
0.71 (0)
0.08 (0.01)
0.73 (0)
0.75 (0)
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Figure 5.6. Segmentation performance of Rad-FIT clustering and established unsupervised clustering
algorithms when segmenting representative center-slice (2-D) of high uptake sphere ROI from background.
(A) True labels for high uptake sphere ROI. (B) Time activity curves for voxels in ROI and background.
(C) Segmentation performance of algorithms when voxels are represented as time activity curves. (D)
Segmentation performance when voxels are represented as FPCs.
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Figure 5.7. Segmentation performance of Rad-FIT clustering and established unsupervised clustering
algorithms when segmenting representative center-slice (2-D) of medium uptake sphere ROI from
background. (A) True labels for medium uptake sphere ROI. (B) Time activity curves for voxels in ROI
and background. (C) Segmentation performance of algorithms when voxels are represented as time activity
curves. (D) Segmentation performance when voxels are represented as FPCs.
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Figure 5.8. Segmentation performance of Rad-FIT clustering and established unsupervised clustering
algorithms when segmenting representative center-slice (2-D) of low uptake sphere ROI from
background.(A) True labels for low uptake sphere ROI. (B) Time activity curves for voxels in ROI and
background. (C) Segmentation performance of algorithms when voxels are represented as time activity
curves. (D) Segmentation performance when voxels are represented as FPCs.

The k-means clustering algorithm had the second highest segmentation
performance across the evaluated unsupervised clustering algorithms when segmenting
individual sphere regions from its surrounding background. This algorithm was
subsequently used to compare performance against the Rad-FIT clustering algorithm to
segment the simulated image into three regions: background, blood, and all spheres. The
Rad-FIT clustering algorithm was able to segment the low uptake spheres from its
surrounding background region and resulted in lower mean percent error in the average
sphere time activity curve (Figure 5.9).
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Figure 5.9. Comparing segmentation performances-three class labels. (A) Representative center slice
image of true segmentation labels (left), segmentation results using K-means clustering (middle), and
segmentation results using Rad-FIT clustering (right) when segmenting simulation images into three
classes: background, blood, and spheres. (B) Average time activity curves for true simulation regions (left),
K-means clustering identified regions (middle), and Rad-FIT clustering (right) identified regions. (C) Mean
percent error and dice scores for segmentation results. The K-means clustering algorithm fails to segment
the low uptake spheres from the background region.
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The k-means clustering algorithm was subsequently used to compare performance
against the Rad-FIT clustering algorithm to segment the simulated image into five
regions: background, blood, low uptake spheres, medium uptake spheres, and high uptake
spheres. The Rad-FIT clustering algorithm was able to segment the low uptake spheres
from its surrounding background region and identify the five regions of distinct tracer
uptake (Figure 5.10). In comparison, the K-means clustering algorithm was unable to
identify and segment the low uptake spheres as a distinct region from its surrounding
background.
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Figure 5.10. Comparing segmentation performances-five class labels. (A) Representative center slice
image of true segmentation labels (left), segmentation results using K-means clustering (middle), and
segmentation results using Rad-FIT clustering (right) when segmenting simulation images into five classes:
background, blood, and low, medium, and high uptake spheres. (B) Average time activity curves for true
simulation regions (left), K-means clustering identified regions (middle), and Rad-FIT clustering (right)
identified regions. (C) Mean percent error, generalized Dice score, and Jaccard indices for segmentation
results. The K-means clustering algorithm fails to segment the low uptake spheres from the background
region, and instead segments the blood region to two separate classes.
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Overall, the Rad-FIT clustering algorithm demonstrated improved segmentation
over the K-means clustering algorithm, as demonstrated by decreased mean percent error
and increased Dice score and Jaccard index for each individual region’s segmentation as
well as segmenting the overall simulated image, measured over ten replicates. Due to this
improved segmentation performance, the Rad-FIT clustering algorithm was utilized as a
4-D unsupervised clustering method towards characterizing functional tumor
heterogeneity as a prognostic biomarker for women diagnosed with locally advanced
breast cancer.
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Chapter 6 : Evaluating the prognostic value of characterizing 4-D
pharmacokinetic functional tumor heterogeneity

This chapter has been adapted from the following:

Chitalia, R., Viswanath, V., Pantel, A.R., Peterson, L.M., Gastounioti, A., Cohen, E.A.,
Muzi, M., Karp, J., Mankoff, D.A. and Kontos, D., 2021. Functional 4-D clustering for
characterizing intratumor heterogeneity in dynamic imaging: evaluation in FDG PET as a
prognostic biomarker for breast cancer. European Journal of Nuclear Medicine and
Molecular Imaging, pp.1-12.

6.1. Introduction
Molecular and functional imaging modalities permit 4-D sampling of disease
burden, capturing both spatial and temporal information that could illuminate various
physiologic behaviors. Dynamic positron emission tomography (PET) imaging can
quantify specific facets of tumor molecular biology
beyond that of static imaging
analog,

18

22,23

7,19,222

and can provide information

. In particular, dynamic PET imaging of the glucose

F-fluorodeoxyglucose (FDG), can provide simultaneous information on

substrate delivery and metabolism

22

. Current clinical characterization of malignant

lesions using PET imaging largely utilizes qualitative descriptors

8

and quantitative

measures based on static radiotracer uptake (e.g. SUVmax) 223.
The emerging field of radiomics has introduced multi-parametric imaging features
extracted with high-throughput computational analysis 33,101,196,224. Previous work by Eary
et al. quantified spatial heterogeneity of radiotracer uptake in static PET imaging and
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demonstrated improved prognostic performance over established clinical markers

225

.

Stoyanova et al. identified sub-regions within pre-clinical dynamic contrast enhanced
(DCE)-MRI images of prostate tumors

226

. Similarly, Cherezov et al. identified tumor

habitats using established radiomic texture features

227

. While such studies demonstrate

the prognostic potential of characterizing 3-D spatial heterogeneity, and are in line with
studies showing differential physiologic functionality across the whole tumor 228,229, these
studies do not fully utilize the combined spatial and kinetic (e.g., 4-D) heterogeneity
information available using imaging probe kinetics from modalities with high temporal
imaging resolution.
The advantages of utilizing kinetic information from dynamic PET imaging have
been demonstrated in breast cancer.

Previous studies have demonstrated predictive

improvement when FDG delivery (K1) and FDG flux (Ki), in combination with [15O]water imaging, were utilized with static SUV measures as markers for neoadjuvant
chemotherapy response in patients with locally advanced breast cancer 22,230,231. However,
these conventional kinetic parameters derived from FDG PET imaging at baseline alone
were unable to show association to disease free survival, likely limited by being derived
from the most metabolically active portion of the tumor, and therefore not fully capturing
intratumor heterogeneity 22.
We have developed a method to characterize 4-D functional tumor heterogeneity
(FTH) by capturing aspects of both spatial and kinetic tumor heterogeneity seen in
dynamic imaging. The improved dynamic sampling and molecular specificity available in
dynamic PET as compared to other imaging modalities may allow for non-invasive,
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novel prognostic and predictive markers to characterize tumor molecular biology. The
developed method is agnostic to the specific radiotracer utilized and does not depend on
complex kinetic modeling assumptions. Instead, the approach is data driven in terms of
identifying intrinsic 4-D patterns of molecular tumor heterogeneity. We present a clinical
proof-of-principle by applying our algorithm on dynamic FDG PET imaging scans of
primary locally advanced breast cancer. We also investigate the role of imaging
signatures as a prognostic biomarker for locally advanced breast cancer and the improved
predictive value of FTH characterization compared to standard dynamic and static
analytic methods for FDG PET.

6.2. Study Cohort
To investigate the role of intratumor segmentation when characterizing functional
heterogeneity, the prognostic value of functional tumor heterogeneity imaging signatures
was explored on a previously published data set where serial dynamic FDG PET was
shown to be predictive of response and recurrence using standard static uptake and
kinetic analysis

22,230,231

. The goal was to test functional tumor heterogeneity imaging

signatures extracted from dynamic FDG PET scans of women with locally advanced
breast cancer imaging prior to treatment and compare their predictive value to standard
approaches.
We used an anonymized data set consisting of women presenting at the University
of Washington Breast Cancer Specialty Center with histologically confirmed breast
carcinoma who underwent dynamic FDG PET imaging prior to neoadjuvant
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chemotherapy and were followed for disease recurrence. The research protocol was
approved by the institutional review board and patients studied provided informed
consent prior to imaging and follow-up. The data set for this analysis was taken from a
study first reported for 35 patients

230

. An additional 30 patients were later studied and

added to a follow-up report of the data 22,231. From this pooled data set of 65 women with
complete baseline dynamic FDG PET scans who also completed neo-adjuvant
chemotherapy and post-therapy surgery, two women were excluded for electing not to
receive chemotherapy, three women were excluded for electing for medical care
elsewhere, four patients were excluded for being unwilling to undergo mid-therapy
imaging, two patients were excluded due to distant disease, and one patient was excluded
due to little or no tracer uptake upon pre-therapy examination resulting in a total of 53
women. Of these, two women were excluded due to image artifacts and one woman was
excluded due to incomplete survival information, resulting in a total of 50 women
included in this study. Dynamic FDG PET images from these 50 women comprised our
study sample reported here. Details of the patient population have been previously
described231.
Of the 50 women included in the data set, 17 women (34%) had recurrence
events. A total of 47 (94%) women were diagnosed with infiltrating ductal carcinoma and
3 (6%) women were diagnosed with infiltrating lobular carcinoma.
Of the non-recurrent cases, 58% were ER positive, 52% were PR positive, and
18% were HER2 positive. Of the recurrent cases, 59% were ER positive, 59% were PR
positive, and 35% were HER2 positive (Table 6.1).
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Table 6.1. Selected study cohort characteristics.
Non-recurrent cases
(n=33,66%)

Recurrent cases
(n=17, 34%)

30-39

5 (15%)

6 (35%)

40-49

14 (43%)

6 (35%)

50-59

13 (39%)

1 (6%)

60-69

1 (3%)

3 (18%)

70-79

0 (0%)

1 (6%)

Infiltrating ductal

31 (94%)

16 (94%)

Infiltrating lobular

2 (6%)

1 (6%)

ER + /HER2 +

2 (6%)

5 (29%)

ER+/ HER2 -

16 (48%)

4 (24%)

ER- /HER2 +

2 (6%)

3 (18%)

ER-/HER2- (Triple negative)

11 (33%)

5 (29%)

8 (24%)

3 (17%)

18, 0 , 2.26

18, 0 , 5.52

Max, min, average (cm)

11, 1.1, 5.2 cm

10, 1.9, 4.9 cm

Ki67 status

27 cases

14 cases

Low

2 (7%)

4 (27%)

Intermediate

2 (7%)

5 (33%)

High

23 (85%)

7 (47%)

Age

Histologic subtype

Receptor subgroup

pCR
Complete response
ALN positivity
Max, min, average
Baseline tumor size
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Each woman had undergone 60-minute dynamic FDG PET centered over the
breast prior to neoadjuvant chemotherapy and breast surgery. All women were imaged in
the supine position and no positioning devices for immobilization were utilized. Women
were infused with 218-396 MBq of FDG over 2 minutes in a 7-10 mL volume, with an
intended injected dose of 370 MBq. Images for all women were acquired on an Advanced
Tomograph (General Electric Medical Systems, Waukesha, WI) using the same image
acquisition protocol. Dynamic images were acquired (25 image frames: 1- min preinjection frame, 4 x 20 s, 4 x 40 s, 4 x 40 s, 4 x 1 min, 4 x 3 min, 8 x 5 min). Images were
reconstructed into 35 x 128 x 128 voxel matrices with a spatial resolution of 10-12
mm230. Clinical information collected as part of the study included hormone receptor
(HR) status consisting of estrogen receptor (ER) and progesterone receptor (PR), human
epidermal growth factor receptor 2 (HER2), clinical stage, tumor size, proliferation
(Ki67), pathologic complete response (pCR), axillary lymph node (ALN) positivity, and
age at diagnosis (Table 6.1). In the study, recurrence free survival (RFS) was tracked for
each patient, defined as date of known recurrence, date of death, or date of most recent
clinical follow-up with no evidence of disease, following the patient’s date of surgery.
Patients received standard of care follow-up including routine period imaging of CT
scans, blood marker analysis (CA2729), and follow-up visits to check for symptoms.
Established ROI-based measures of uptake and kinetics for dynamic FDG PET –
summed imaged standardized uptake value (SUV), and the kinetic parameters of FDG
blood-to-tissue transport (K1) and FDG trapping flux (Ki) - were calculated based on
kinetic modeling of dynamic data for each woman and have been previously
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reported22,230. These kinetic parameters were measured for each tumor from a 1.5 cmdiameter circle VOI surrounding the area of maximal tumor FDG uptake seen on the 3060m summed image.

6.3. Functional tumor heterogeneity (FTH) signature extraction
A 3-D bounding region surrounding each unifocal lesion was manually identified
by a radiologist blinded to the outcome of each patient using the final of the summed
FDG images for the 25 imaging frames (30-60 minutes post-injection) and guided by
ROIs previously used for extraction of SUV, K1, and Ki for consistency. An established
segmentation approach was applied to the TACs generated from the 25 imaging frames
of each voxel within the bounding region to segment the tumor from its surrounding
background217.
Within the segmented 3-D tumor region, Rad-FIT clustering was applied to
segment each tumor region into three, spatially constrained sub-regions with distinct
functional behavior. Three sub-regions were selected based on the rationale that there are
currently three major subtypes of breast tumors broadly recognized: hormone receptor
positive, HER2 positive, and triple negative4. The three sub-regions within each tumor
were ranked in order of descending mean value of the first FPC to allow for consistent
comparisons across tumors.
The resulting Rad-FIT clustering within each tumor was summarized using
metrics describing sub-region compactness and separation. These metrics were chosen to
summarize how well the functional behavior of each tumor will cluster into three groups
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and to allow for comparisons of intratumor heterogeneity across women. Compactness
was measured using the between cluster sum of squares (BCSS) scaled by the total sum
of squares (TSS) :
Eq. 6.1

where K represents the 3 sub-regions and N is the total number of voxels within each
tumor. The separation between sub-regions was determined using the Bhattacharya
distance

232

to calculate the distance between FPC distributions of two sub-regions,

represented as ϕ and defined as:
Eq. 6.2

Use of this distance allows for a similarity measure between the distributions of FPC
values within two sub-regions.
Based on the definitions above, a total of four features summarizing intratumor
heterogeneity from Rad-FIT clustering results were extracted to form an FTH signature
(Figure 6.1): (1) BCSS/TSS, (2) distance between sub-region 1 and 2 (ϕ(1,2)), (3)
distance between sub-region 2 and 3 (ϕ(2,3)), and (4) distance between sub-region 1 and
3 (ϕ(1,3)).
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Figure 6.1. FTH signature extraction. (A) 3-D tumor region identified by a radiologist shown in green. (B)
Automated 3-D segmentation of tumor from background with pixels represented using time activity curves.
(C) Rad-FIT clustering performed, identifying three, spatially contiguous sub-regions. (D) Cluster
compactness and cluster separation distances are calculated to form features in FTH signature. (E)
Intratumor heterogeneity summarized using the FTH signature.

BCSS/TSS provides a measure of how compact the resulting clusters are; the
more compact each cluster is, the greater heterogeneity between the identified subregions. Calculating the distance between the distributions of FPC values of two subregions provides a metric for how separated the clusters are; a greater distance between
sub-regions indicates greater heterogeneity within the whole tumor region. This FTH
signature can be used to interpret how distinct the three identified sub-regions are within
each tumor. As such, the average value of the FTH signature, or FTH signature index,
can provide a metric for intratumor heterogeneity across tumors.

6.4. Statistical Analysis: Evaluation of FTH signatures as a prognostic
biomarker
Our goals in this proof of principal study were to test the prognostic value of FTH
signatures from dynamic breast cancer FDG PET and to assess for incremental value
compared to standard clinical parameters and conventional FDG PET static and dynamic
analysis measures used in prior published analyses. FTH signatures were first z-score
normalized across all women. Time-to-event analysis was then used to assess the
prognostic value of the FTH signatures in predicting recurrence-free survival (RFS). To
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this end, a three-fold cross validated (CV) Cox proportional hazards model was used to
compare improved prognostic discriminatory capacity over baseline models of
established prognostic factors consisting of ER status, PR status, tumor size, pCR, and
ALN positivity and kinetic parameters consisting of the SUV, K1, and Ki. These
prognostic factors were chosen based on the available data as well as the intent to
compare analysis results to prior published data 22,230,231.
Model performance was evaluated using an averaged C-statistic over the test sets
for all three folds and the log-likelihood statistical test.
The prognostic value of the FTH signature was evaluated via Kaplan-Meier
survival analysis using each patient’s risk core, dichotomizing patients into high and low
risk groups. The risk score for each patient was defined as the patient’s FTH signature
weighted by the corresponding coefficients from each of the three test sets from a 3-fold
cross validated model for each covariate in the FTH signature

184,224

. Risk scores

generated from baseline features of ER status, PR status, tumor size, pCR, and ALN
positivity and from baseline and kinetic features were also assessed. Statistical
significance of Kaplan-Meier stratification was evaluated using the Log Rank Test.
Lastly, an exploratory unsupervised hierarchical clustering was performed on the
extracted FTH signatures from each tumor. The resulting c clusters obtained from the
hierarchical clustering algorithm were interpreted as c intrinsic FTH phenotypes seen in
this study population.
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The optimal number of stable FTH phenotypes was determined using consensus
clustering166. Statistical significance of the identified, stable FTH phenotypes was
evaluated using the SigClust method167.
The distribution of histopathologic and kinetic prognostic covariate values across
tumors assigned to each of the FTH phenotypes was assessed using chi-square tests for
categorical biomarkers and one-way analysis of variance test for continuous biomarkers.

6.5. Results Evaluation of the FTH signature as a prognostic biomarker
Representative tumor images after Rad-FIT clustering demonstrate intratumor
heterogeneity within breast tumors (Figure 6.2). Tumors with increased intratumor
heterogeneity can be identified as having sub-regions with distinct time activity curve
behaviors, while tumors with decreased intratumor heterogeneity display little distinction
between the time activity curve behavior of the identified sub-regions.
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Figure 6.2. Representative images for the primary tumors of two women diagnosed with locally advanced
breast cancer with future tumor recurrence (top) or tumor non-recurrence (bottom). (A) representative slice
from an early frame at less than 5 minutes after tracer injection, (B) representative slice from middle frame
at 15 minutes after tracer injection, and (C) representative slice from final frame taken at 60 minutes after
tracer injection of a 57-year old, post-menopausal woman with a high grade, ER-, PR+, HER2-, tumor who
had disease recurrence upon follow-up (top). (D) Three sub-regions identified using Rad-FIT clustering
labeled as region 1 (red), 2 (blue), and 3 (green), and (E) average TACs for each identified sub-region. (F)
A representative slice from an early frame at less than 5 minutes after tracer injection, (G) slice from
middle frame at 15 minutes after tracer injection, (H) and representative slice from final frame taken at 60
minutes after tracer injection of a 36-year old, pre-menopausal woman with a high grade, ER+, PR-, HER2, tumor with no disease recurrence (bottom). (I) Three sub-regions with distinct 4-D behavior identified
using Rad-FIT clustering labeled as region 1 (red), 2 (blue), and 3 (green), and (J) average time activity
curves for each identified sub-region.

As expected, in a full multivariate Cox proportional hazards model after adjusting
for ER status, PR status, tumor size, pCR, and ALN positivity (Table 6.2), ϕ(1,2) and
ϕ(2,3) were associated with disease free survival (Table 6.3).

122

Table 6.2. Risk of breast cancer recurrence in Hazzard Ratios (HR) associated with
baseline model.
Covariate

HR

95% CI

p-value

ER status

1.17

0.24-9.98

0.87

PR status

0.51

0.05-4.8

0.55

Tumor size

0.99

0.82-1.22

0.99

pCR

1.12

1.01-1.21

0.01 *

ALN positivity

0.85

0.23- 3.15

0.81

Table 6.3. Risk of breast cancer recurrence associated with FTH imaging signature
adjusting for baseline and kinetic features.
Covariate

HR

95% CI

p-value

BCSS/TSS

1.08

0.62-1.89

0.77

ϕ(1,2)

0.04

0.002-0.66

0.02*

ϕ(1,3)

0.82

0.48-1.39

0.46

ϕ(2,3)

14.08

2.41-21.18

0.003*

A baseline, three-fold CV Cox proportional hazards model consisting of ER
status, PR status, tumor size, pCR, and ALN positivity resulted in a mean C-statistic of
0.51 when predicting RFS. Adding SUV, K1, and Ki parameters to the baseline model
resulted in a mean CV C-statistic of 0.54. Adding the FTH signature to the baseline
model improved the mean CV C-statistic to 0.74 (p < 0.01) (Figure 6.3A).
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Dichotomizing patients into low- and high-risk groups based on the baseline
model risk scores (Figure 6.3B) and baseline plus the kinetic model risk scores (Figure
6.3C) demonstrated no statistically significant separation between Kaplan-Meier curves.
Patient dichotomization into low- and high-risk groups based on the baseline plus FTH
signature risk scores (Figure 6.3D) resulted in a statistically significant separation
between Kaplan- Meier curves (p< 0.05) for RFS probability.

Figure 6.3. FTH survival analysis. (A) Cross validated c-scores and Kaplan-Meier survival curves for
baseline (ER status, PR status, tumor size at baseline, pCR, and ALN positivity), baseline plus kinetic (ER
status, PR status, tumor size at baseline, pCR, ALN positivity, SUV, K 1, Ki) and baseline plus FTH
signature models. Kaplan-Meier curves generated when patients are stratified by risk scores generated from
(B) the baseline model, (C) baseline plus kinetic features model, and (D) baseline plus FTH signature
model.

Unsupervised hierarchical clustering of women based on the extracted FTH
signatures from each tumor identified two clusters which were interpreted as FTH
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phenotypes seen in the study population and found to be statistically significant via the
SigClust method (p=0.04) (Figure 6.4A).
As a higher FTH signature index suggests greater separation between the three
sub-regions’ FPC values and can therefore be interpreted as greater intratumor
heterogeneity, the identified FTH phenotypes were ranked based on the mean FTH
signature index found across all women assigned to each phenotype. The resulting FTH
phenotypes 1 and 2 were interpreted as a low FTH versus high FTH phenotypes,
respectively, with tumors in phenotype 1 having lower mean FTH signature indices (blue
color in Figure 6.4A), versus tumors in phenotype 2 which had on average higher FTH
signature indices (red color in Figure 6.4A).
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Figure 6.4. FTH phenotypes. (A) Unsupervised hierarchical clustering of FTH signatures identifies 2
significant phenotypes of FTH, with clinical covariate distribution across identified phenotypes displayed
in the bottom legend. The resulting cluster dendrogram can be seen above a heatmap in which each row
represents a feature within the FTH signature, and each column represents a tumor (B) Distributions of Ki
across the identified phenotypes were found to be statistically significant (p<0.05).

Tumor PR status was found to be statistically significantly different across the
two FTH phenotypes (p<0.05), with tumors in the low FTH phenotype having a higher
proportion of PR positive tumors. Other clinical covariates including ER status, HER2
status, Ki67 status, pCR, ALN positivity, and tumor grade were not statistically
significant across identified phenotypes. From the FDG PET covariates, Ki was found to
be statistically significantly different across the two phenotypes (p<0.05), with tumors in
the high FTH phenotype having a greater interquartile range (0.025) and greater variance
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(0.0003) than tumors in the low FTH phenotype (interquartile range: 0.004, variance:
3.27e-5) (Figure 6.4B). K1 and SUV values were not found to be statistically significant
across the identified phenotypes.

6.6. Discussion
Our results suggest that incorporation of both spatial and kinetic information in a
4-D dynamic activity curve clustering paradigm allows for improved segmentation of
dynamic PET imaging data over established unsupervised clustering techniques utilizing
kinetic information alone. Established unsupervised voxel parcellation techniques largely
assume voxel independence8, and as such, may be inadequate for identifying spatially
constrained, functionally similar sub-regions under the hypothesis that sub-clonal
populations can occupy spatially contiguous regions with common biologic properties 39.
Along these lines, partial volume effects seen in imaging modalities suggest that
neighboring voxels may share information regarding underlying tissue structure due to
the spatial limitations of the imaging device204. Therefore, analyzing imaging
presentations of intratumor heterogeneity requires a fully 4-D approach.
We had the goal of developing methodology broadly applicable to PET tracers
with similar kinetic features. With this in mind, dynamic simulations utilized for Rad-FIT
development and validation (Chapter 5) were based on FLT simulated data and used to
select an approach which was then applied to a previously collected FDG patient dataset
to examine the role of FTH as a prognostic biomarker. The rationale was that while
simulation curves were generated using kinetic parameters specific to FLT (flux between
0.03-0.1 mL/min/g), these kinetics curves have parameters similar to FDG PET curves
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(flux between 0.02 - 0.09 mL/min/g), and they can be generalized to all tracers fit to a
two-compartment model, including FDG, as long as the model and range of parameters
has overlap with these tracers. Additionally, and as our algorithm is in principle agnostic
to the type of tracer used or any related kinetic modeling parameters, utilizing simulated
images of a different two-compartment radiotracer during Rad-FIT development allowed
for a more generalizable algorithm that was not biased towards a single specific tracer in
subsequent analyses.
Extending the Rad-FIT clustering algorithm to characterize intratumor
heterogeneity has the potential to identify intratumor sub-regions with discrete functional
behavior. This is supported by the average TACs from the identified sub-regions in
representative tumors (Figure 6.2), where the tumor with disease recurrence clustered
into three sub-regions with distinct curve patterns. The tumor with no disease recurrence
and characterized as ER+, demonstrated mostly low uptake and non-rising curves in the
identified sub-regions.
Quantifying intratumor heterogeneity using the FTH imaging signature
demonstrates

prognostic

value

when

predicting

RFS.

Cox-regression

models

incorporating FTH signatures added to a baseline model demonstrated a statistically
significant improvement in C-statistic. While the dichotomization of baseline risk scores
based on known prognostic features did not demonstrate significant Kaplan-Meier curve
separation in this relatively small sample size, consistent with previous analyses of this
study cohort22,231, improvement over models combining baseline and kinetic features
emphasizes the added prognostic value of utilizing quantitative features summarizing
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dynamic tumor behavior over the entire volume. Additionally, risk scores generated using
the baseline features and FTH signature resulted in statistically significant patient
dichotomization into low- and high-risk groups for RFS using Kaplan-Meier survival
analysis as compared to risk signatures generated from the baseline model and baseline
plus kinetic model.
While prior studies have shown prognostic value for measures obtained from
serial dynamic FDG PET using standard kinetic analysis methods231, pre-therapy FDG
dynamic data were not significantly predictive. Similarly, prior studies demonstrated the
predictive value of pre-therapy measures of FDG flux and tumor blood flow obtained
from combined 15O-water PET and FDG PET studies 230,231, but pre-therapy FDG kinetic
measures alone were not significantly predictive of RFS. In this preliminary analysis, use
of the Rad-FIT clustering algorithm extracted significantly prognostic 4-D signatures
from pre-therapy dynamic FDG PET data that did predict RFS, a notable incremental
improvement on standard approaches to dynamic PET analysis of considerable potential
significance.
Additionally, our results suggest that intrinsic imaging phenotypes may exist
within locally advanced breast tumors corresponding to FTH. In particular, statistically
significant differences in the FDG flux constant, Ki, were seen across the two phenotypes
with tumors corresponding to higher degrees of FTH having higher values of Ki. This
finding suggests that the tumor characteristic of increased metabolic rate may be captured
within the FTH imaging signature generated from the 4-D clustering performed using
Rad-FIT and may have prognostic significance when expanded to a larger study cohort.
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Interestingly, compared to tumor clinical and histopathologic features we found
significant differences across the FTH phenotypes in PR expression, a marker shown to
be an indicator of tumor ER functionality and a more differentiated breast cancer biologic
phenotype 233.
Limitations of our study should be noted. First the Rad-FIT clustering algorithm
utilizes K-means clustering as an initialization to the method, which can allow for
sensitivity to cluster initialization due to K-means clustering identifying local optima.
Future studies will be conducted to evaluate segmentation performance when random
cluster initializations are selected. Additionally, our study utilized a relatively small
sample size of patients. To account for potential model overfitting, we utilized three-fold
CV in our time-to-event analysis, to ensure model robustness. The identification of FTH
phenotypes within the study population is limited by a lack of independent validation and
instead was conducted as an exploratory analysis. Future work will include expanding
this initial, exploratory analysis to a larger cohort as well as validating the identified FTH
phenotypes. While the Rad-FIT clustering paradigm identified three clusters within each
tumor, the optimal number of functionally discrete sub-regions may vary across tumors.
In this exploratory study, the selection of three for the number of subtypes was chosen
empirically, guided by the three major subtypes of breast cancer (ER+/PR+, Her2+,
Triple negative). Future work will also include optimization of the Rad-FIT clustering
algorithm such that an optimal number of clusters is identified within each tumor. In
addition, we have evaluated only the pre-therapy time point in this initial analysis. All
women included in our study underwent neoadjuvant chemotherapy and repeat mid130

therapy imaging. To account for the effect of treatment on intratumor heterogeneity and
corresponding FTH signatures, we plan to expand our analysis to dynamic FDG PET
images taken also during the midpoint of each woman’s therapy in a future study. Lastly,
alternative approaches exploring a linear analysis of 4-D dynamic PET using a mixturebased approach have been previously reported 234,235. Future work will include expanding
our analysis to compare methodologies and potentially include a mixture-based
component. Lastly, we developed and applied this method on simulated dynamic images
and clinical dynamic scans of breast cancer patients, with a larger goal of extending this
method towards analyzing other solid tumors and different PET tracers in future work.

6.7. Conclusion
In conclusion, we have developed a 4-D clustering and segmentation algorithm to
identify functionally discrete, spatially constrained sub-regions within breast tumors that
was able to generate prognostic measures from pre-therapy dynamic FDG PET of locally
advanced breast cancer not previously identified by ROI-based kinetic analysis. Our
results demonstrate that quantifying functional tumor heterogeneity can provide
independent and additional prognostic value and may provide a non-invasive- 4-D
characterization of breast tumors towards personalized decision making.
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Chapter 7 : Extended functionalities of Rad-FIT clustering: exploring
the feasibility of an unsupervised method to summarize 4-D
pharmacokinetic spatial heterogeneity

7.1 Introduction
We have explored extending the functionalities of a novel 4-D clustering
approach to model spatially constrained, functionally discrete sub-regions within breast
tumors and extract factors that summarize this heterogeneity. We have previously
assessed the initial clinical applications of this approach in developing personalized
prognostic imaging signatures characterizing breast tumor heterogeneity by using a fixed
number of sub-regions236. In this preliminary work, we remove this constraint by using a
multivariate Kullback-Leibler divergence-based minimization approach to automatically
determine the optimal number of sub-regions for each tumor. We then perform an
evaluation of this unsupervised 4-D segmentation algorithm using simulated image
phantoms modeling heterogeneous breast lesions. We compare the segmentation
performance of the developed algorithm against established unsupervised clustering
algorithms.

7.2 Rationale for unsupervised method
Initial development and applications of using Rad-FIT clustering to summarize
intratumor heterogeneity involved a pre-determined number of sub-regions for the
algorithm to identify (Chapters 5 and 6)236. Preliminary exploration of FTH as a
prognostic biomarker resulted in predefining the number of intratumor sub-regions to
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three, assuming the three broad receptor subtypes for breast cancer (Chapter 6)236.
However, the degree of intratumor heterogeneity across breast tumors may vary and as
such, we wanted to extend Rad-FIT clustering to determine the optimal number of subregions within a single tumor in an unsupervised manner. Furthermore, molecular
heterogeneity may go above and beyond the three broad histopathologic subtypes
(ER+/PR+, Her2+, Triple negative), and we aimed to develop an approach where this
determination could be more data driven. Identifying the number of functionally discrete
sub-regions, unique to a tumor, may also allow for precise longitudinal monitoring of
changes in intratumor heterogeneity, including identifying potentially emerging
heterogeneity due to de-novo treatment resistance.

7.2 Heterogeneity phantom images
Four sets of large heterogeneous lesions were simulated using GATE v8.1211 and
cropped into four separate 4-D images with dimensions of 71 x 71 x 68 x 70 frames. Each
image consisted of a set of three 10-cm-diameter spheres, with centers placed in the same
axial location 5 cm apart from each other to form an equilateral triangle. This allowed for
overlap of the edges of the spheres to emulate a large heterogeneous lesion, where
overlapping areas had the combined activity of each sphere. The four sets of spheres had
the following activity to background ratios at 60-min post-injection: Simulation 1) 2:1,
2:1, 2:1; Simulation 2) 2:1, 3:1, 4:1; Simulation 3) 4:1, 6:1, 8:1; and Simulation 4) 10:1,
20:1, 30:1 (Figure 7.1).
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Figure 7.1. Diagrams of simulated heterogeneity phantoms demonstrating sphere overlap and the resulting
flux scales for overlapping regions in simulation 1 (A), simulation 2 (B), simulation 3 (C), simulation 4
(D).

Time activity curves (TACs) within each of the simulated images were based on
previous FLT dynamic simulations where the background TAC is based on muscle data
and the 2:1, 4:1, and 8:1 contrast spheres were based on previously shown213 low,
medium, and high flux spheres, respectively. Higher contrast spheres were simulated
based on scaled TACs of the high flux sphere. Simulated data were binned into 70 frames
(17 x 1.2 s, 10 x 2.4 s, 12 x 4.8 s, 4 x 12 s, 11 x 30s, 4 x 60s, 6 x 180s, 6 x 300s ),
reconstructed using list-mode TOF OSEM237 and binned into 2 mm isotropic voxels. The
true number of discrete functional regions was determined based on the spatial location
and average activity value of the region, resulting in: Heterogeneity simulation 1: three
clusters, Heterogeneity simulation 2: five clusters, Heterogeneity simulation 3: seven
clusters, Heterogeneity simulation 4: six clusters (Figure 7.2).
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Figure 7.2. The discrete sub-regions within each heterogeneity simulation. The number of regions within
the heterogeneity image based on the flux scaling of overlapping sphere regions and corresponding voxel
time activity curves and mean time activity curves for each individual region in simulation 1 (A),
simulation 2 (B), simulation 3 (C), and simulation 4 (D).

7.3 Determining optimal number of clusters
In order to select the optimal number of clusters within each tumor, we amended
the methodology initially presented by Eloyan et al.220 to incorporate multivariate
Gaussian distributions of voxel representations and Markov Random Field (MRF)-based
prior probabilities for each voxel.
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The goal for determining an empirical estimation of true voxel labeling
assignment is to minimize the distance between the estimated probability function of a
distribution with its true underlying distribution. To that end, when the optimal number of
cluster sub-regions, unique to a specific tumor, is determined, the Kullback-Leibler (KL)
divergence

between

true

and

estimated

final

probability density will be 0.
However, as the true probability density for the tumor image is unknown, the
difference in this KL divergence moving from k to k+1 clusters is leveraged such that:
Eq. 7.1

This ratio can be empirically estimated for each voxel moving from k to k+1 clusters as:
Eq. 7.2

and summarized over all voxels as:

Eq. 7.3
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This metric is calculated across an array of values for k, and the value K at which a
minimum is reached is selected as the optimal number of sub-regions.

7.4 Beta parameter selection

While previously implemented Rad-FIT clustering utilized a set value for
the floating parameter, β, based on signal to noise variation across the simulated images,
it is likely that the optimal value of β will vary across tumors. This is due to variations in
image acquisition and reconstruction protocols resulting in varying image signal to noise
ratios and varying partial volume related effects seen across clinical images. As such, the
dependency of a voxel’s sub-region classification on its surrounding neighborhood may
vary.
A previous study by Eloyan et al220. assessed parameter values of 4, 6, and
12 and found no significant difference in the resulting image clustering. Ultimately, the
authors selected the smallest value of beta that prevented losing image sharpness. When
evaluating the final number of sub-regions within tumors from a previously analyzed
cohort of dynamic FDG PET images of invasive breast cancer236 when beta parameter
values ranged from 0.75 to 3, we saw large variations in the resulting number of subregions as well as their spatial distribution within a tumor (Figure 7.3).
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Figure 7.3. Representative breast lesion segmented using U-Rad-FIT clustering at varying values of beta.
Representative frame of dynamic PET image (A) and lesion ROI (B). Resulting cluster segmentations and
each region’s average time activity curves when using beta = 0.75 (C), beta= 1(D), beta =2 (E), and beta =3
(F). Smaller values of beta result in varying numbers of sub-regions, likely picking up image noise.

This suggested that not only is selection of an optimal value required for
each tumor, but also that the value of the beta parameter should be larger to avoid
characterizing image noise as unique sub-regions. When larger values of beta are selected
(e.g. beta= 6) resulting average time activity curves from the U-Rad-FIT derived subregions demonstrate discrete curve behavior and result in more anatomically realistic subregions in relation to the lesions’ size (Figure 7.4).
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Figure 7.4. Representative lesion segmented using U-Rad-FIT clustering using a beta value of 6 (A). Each
identified sub-region’s average time activity curves (B), and all voxels represented as FPCs (C). Using a
larger value of beta allows for a more physiologically likely number of identified sub-regions, as larger
spatial weights on prior probabilities may result in less sensitivity to image noise.

Therefore, to account for variations in signal to noise across images and to select the
optimal value of the floating beta parameter unique to each lesion, we implemented a
selection criterion for choosing a value of beta which maximizes inter-cluster separation
and minimizes intra-cluster variance in time (functional principal component) and space
domains. To implement this, we leveraged the Calinski-Harabasz (CH) index238
calculated for both FPCs and spatial coordinates:
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Eq. 7.4

Eq. 7.5

Eq. 7.6

where

is the number of points in cluster k,

set,

is the fpc centroid of cluster k, and

k. Similarly,

is the FPC centroid of the entire data
is the fpc value for voxel,

, in cluster

is the spatial coordinates of the centroid of the entire data set,

is the spatial coordinates of the centroid of cluster k, and
coordinates for voxel,

is the spatial

, in cluster k. The total number of voxels is defined as n and K is

the total number of clusters.
The value of β resulting in the highest modified CH index (

, was

selected as the optimal value for that tumor. This would result in selecting the value of β
that resulted in the most compact and well-separated clusters in time and space.
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7.5 Unsupervised Radiomic Functional Intratumor (U-Rad-FIT) clustering
As a result of determining the optimal number of sub-regions using the
optimized value for the floating parameter, β, the algorithm for Rad-FIT clustering has
been extended to Unsupervised Radiomic Functional Intratumor (U-Rad-FIT) clustering,
and can be defined as follows in below in Algorithm 1:
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Algorithm 7.1. Unsupervised Radiomic functional intratumor (U-Rad-FIT) clustering
Input: Vi ∈ R3×t,
(floating parameter),
(number of sub-regions)
Output: z ∈ [0,1]K (Clustering Assignment)
Step 1: Functional principal component analysis (retain components with 85% of variance:
V(x,y,z,t) » V(x,y,z,f)
for k = 1…Κ
for
Rad-FIT Clustering:
Initialization: Initialize z,
by K-means clustering algorithm
Loop- Repeat (t) until convergence
Expectation step: Fix z,

Solve for
Maximization step:

end
(see Eq. 4 and 5)
Rad-FIT Clustering (
Calculate KL divergence metric from k and k+1:
end

while
calculate
for

7.6 Evaluating performance of U-Rad-FIT clustering
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The performance of U-Rad-FIT clustering in identifying and segmenting the
number of discrete functional regions was evaluated in each heterogeneity image and
compared against the performance of K-means clustering with voxels represented both as
time activity curves and as functional principal components (FPCs). Segmentation
performance was evaluated using the Dice score, with generalized and region-based Dice
scores evaluated for each image. K-means clustering was applied using the optimal
number of clusters identified by U-Rad-FIT clustering to ensure robust comparisons.
Using the methodology outlined above for U-Rad-FIT clustering, the optimal
number of functional clusters, in heterogeneity images 1 through 4 was determined to be
three, five, six, and six, respectively. The overlap of spheres in each of the simulated
images, with varying activity to background ratios, results in heterogeneous lesions with
varying difficulties of separability.
When comparing the generalized segmentation performance of U-Rad-FIT
clustering against K-means clustering with voxels represented as time activity curves and
FPCs and segmenting the tumor into the same number of clusters, U-Rad-FIT clustering
demonstrated the highest performance overall (Figure 7.5). All three segmentation
approaches performed similarly on heterogeneity simulation 1. In heterogeneity
simulations 2-4, which represented more challenging spatial and functional
heterogeneity, U-Rad-FIT clustering demonstrated better performance.
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Figure 7.5. Generalized Dice score performance for each simulated heterogeneity image. True
segmentation labels of 3 cluster-regions, K-means clustering results with voxels represented as TACs, Kmeans clustering results with voxels represented as FPCs, and U-Rad-FIT clustering results for
Heterogeneity simulation 1 (A). True segmentation labels of 5 cluster-regions, K-means clustering results
with voxels represented as TACs, K-means clustering results with voxels represented as FPCs, and U-RadFIT clustering results for Heterogeneity simulation 2 (B). True segmentation labels of 6 cluster-regions, Kmeans clustering results with voxels represented as TACs, K-means clustering results with voxels
represented as FPCs, and U-Rad-FIT clustering results for Heterogeneity simulation 3 (C). True
segmentation labels of 6 cluster-regions, K-means clustering results with voxels represented as TACs, Kmeans clustering results with voxels represented as FPCs, and U-Rad-FIT clustering results for
Heterogeneity simulation 4 (D).

Comparing region-based segmentation performances on each the four heterogeneity
simulations, against K-means clustering with voxels represented as FPCs, which was the
higher performing control segmentation, U-Rad-FIT clustering demonstrated improved
Dice scores for each region (Figure 7.6).
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Figure 7.6. Region based Dice scores for each heterogeneity simulation image using K-means clustering
with voxels represented as FPCs and U-Rad-FIT clustering.

7.7 Conclusion
This exploratory work demonstrates an initial extension of Rad-FIT clustering to
be unsupervised, without a predefined number of sub-regions to segment. Initial
experiments in developing U-Rad-FIT clustering suggests an improved segmentation
performance when identifying and segmenting the true number of functionally discrete
sub-regions as compared to conventional unsupervised clustering techniques. Also,
preliminary experiments in selecting the optimal β parameter controlling the spatial
influence in segmentation suggest that varying lesions may have a varying optimal
parameter based on image signal to noise ratios. U-Rad-FIT clustering may be used in its
originally developed format in which the number of sub-regions to identify is pre145

determined, or further validation of U-Rad-FIT clustering may result in identifying the
optimal number of sub-regions in breast lesions. Further work is required to validate the
identified sub-regions through ground truth histology/immunohistochemistry mapping for
a physiologic interpretation of the kinetic variations displayed across the different subregions.
Potential applications of U-Rad-FIT clustering may include longitudinal
monitoring of changes in the number of sub-regions or sub-region kinetic properties over
the course of chemotherapy for detection early response or non-response to treatment,
including the emergence of de-novo treatment resistance. Longitudinal changes in the
number of sub-regions within a lesion may allow for non-invasive characterization of an
increase or decrease in lesion heterogeneity, or for identification of more aggressive or
resistant sub-clonal populations. Lastly, sub-regions identified using U-Rad-FIT
clustering may be spatially registered to histological or other radiographic images for a
multi-modal understanding of physiological differences across tumor sub-clones.
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Chapter 8 : Extended applications of quantifying lesion heterogeneity
and future directions

8.1 Future directions: extending applications to pre-cancerous lesions
towards personalized medicine
While the scope of this thesis has been largely aimed towards exploring predictive
and prognostic imaging biomarkers for invasive breast cancer, these methods to quantify
lesion heterogeneity may be extended to invasive lesions in varying anatomic site and to
pre-cancerous breast lesions. While the incidence rate of invasive breast cancer remains
high for women, diagnoses of pre-invasive intra-ductal proliferations such as ductal insitu carcinoma (DCIS), have increased as a result of increased breast cancer screening,
and comprise approximately 25% of diagnosed breast cancers239. Treatment of DCIS
largely follows that of invasive breast cancer: radiation treatment and/or endocrine
therapy. However, it is estimated that less than 40% of diagnosed DCIS cases will
progress to invasive disease240. As such, improved stratification of low-risk and high-risk
DCIS cases is required to allow for personalized treatment strategies to reduce over
treatment by local and systemic therapies. Current histopathologic biomarkers may be
limited in stratifying low-risk vs high-risk cases due to inadequate sampling of disease
burden and heterogeneity.
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8.1.1 Discovery study cohort and feature generation

As a preliminary analysis to explore the potential of imaging phenotypes of DCIS
heterogeneity, we retrospectively analyzed of cohort of 163 women from the previously
conducted E4112 trial by the American College of Radiology Imaging Network
(ACRIN). For each woman, DCE-MRI imaging was performed, with images acquired
across 34 different sites following a standardized study protocol. The in-plane resolution
of the images ranged from 0.35-1.25 mm/pixel, and were acquired on either 1.5T or 3T
scanners. For this preliminary analysis, the pre-treatment, pre-operative images were
evaluated for each woman. Clinical covariates including DCIS score, lesion grade, and
comedonecrosis were available for each woman. First, all images were preprocessed
using N4 bias field normalization241. For each case, the 3-D primary lesion was
segmented by a trained radiologist from the first-post contrast image. To promote
comparability in analysis across images from varying clinical sites, all images were
resampled using a linear interpolation to the lowest resolution scan in the dataset. Within
each lesion in the first-post contrast image, 95 radiomic features were extracted using the
Cancer Imaging Phenomics Toolkit (CaPTk)163. All extracted features were z-score
normalized across all tumors and features were sign normalized such that increased
feature value indicates increased tumor heterogeneity. To avoid bias from non-uniform or
heavily skewed features in this exploratory analysis, features were selected with the
relatively strict criteria of having IQR >1 and skewness >5. This resulted in a total of 32
radiomic features.
148

8.1.2 Imaging phenotypes of DICS heterogeneity
To identify intrinsic imaging phenotypes of DCIS, unsupervised hierarchical
clustering was performed on the extracted, 32-feature feature vector for tumors in the
discovery cohort. The k clusters obtained from the unsupervised hierarchical clustering
algorithm were interpreted as imaging phenotypes seen in the population. Clustering was
performed using the Euclidean distance between tumor feature vectors and Ward’s
minimum variance method was used as the clustering criterion.

Two statistically

significant phenotypes were identified in the discovery cohort and found to be stable
using Consensus Clustering166 and significant via SigClust167 methods (p<0.001) (Figure
8.1). Distributions of DCIS score, lesion grade, and necrosis were evaluated across the
identified imaging phenotypes with necrosis found to be statistically significant (p=0.02)
(Figure 8.2).
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Figure 8.1. Identification of intrinsic imaging phenotypes of DCIS tumor heterogeneity. Unsupervised
hierarchical clustering of SER features identifies three intrinsic phenotypes in the discovery cohort.
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Figure 8.2. Associations between histopathologic prognostic markers and heterogeneity phenotypes
identified in the discovery cohort. Distribution of DCIS scores across heterogeneity phenotypes (A).
Number of grade 1, grade 2 and grade 3 lesions across heterogeneity phenotypes(B). Number of low,
intermediate, and high DCIS scores across heterogeneity phenotypes (C). Number DCIS lesions with and
without comedonecrosis across heterogeneity phenotypes (D).

8.1.3 Validation study cohort

A retrospective, exploratory validation cohort242, provided by the University of
Washington, was utilized in this analysis to validate the DCIS imaging phenotypes. The
validation cohort consisted of 20 patients with DCIS who underwent preoperative DCEMRI at the University of Washington between 2004 and 2014 with ipsilateral recurrence
more than 6 months after definitive surgical treatment were retrospectively identified.
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For each patient, a control subject with DCIS that did not recur was identified and
matched on the basis of clinical, histopathologic, and treatment features including, age,
menopausal status, presence of a high risk genetic mutation, DCIS Van Nuys Pathologic
grade, presence of comedonecrosis, estrogen receptor status, final surgical margins,
postsurgical endocrine therapy, and postsurgical radiation therapy. Therefore, of the 20
patients included in the validation cohort, 10 patients had a future event of recurrence and
10 did not. Median time to recurrence was 14 months, and median follow-up for control
subjects was 102 months.

8.1.4 Validation of imaging phenotypes of DCIS lesion heterogeneity
In order to validate the imaging phenotypes of DCIS lesion heterogeneity
identified in the discovery cohort, the first post-contrast DCE-MRI images from the
validation cohort were preprocessed as detailed above. From the resampled first postcontrast lesions, the same 32 radiomic features as selected from the discovery cohort
were extracted using CapTK.

Features in the validation cohort were first z-score

normalized across tumors and sign normalized such that an increasing feature value
corresponded to an increase in lesion heterogeneity. Unsupervised hierarchical clustering
was then applied to the validation cohort tumors using the 32-feature feature vector. Two
significant imaging phenotypes were also identified in the validation cohort through
clustering analysis and determined to be stable and significant (p=0.0001) using
ConsensusClustering and SigClust methods, respectively. The in-group proportion (IGP)
statistic243 was used to determine whether the imaging phenotypes identified in the
discovery cohort existed in the validation cohort. Imaging phenotypes were found to have
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high consistency between the discovery and validation cohorts with IGP values of 90%
and 99% for Phenotype 1 and Phenotype 2, respectively. The IGP for Phenotype 2 was
found to be significant (p=0.02) (Figure 8.3).

Figure 8.3. Independent validation of intrinsic imaging phenotypes of tumor heterogeneity. Phenotypes
identified in the discovery cohort (A) are significantly reproducible in the validation cohort (B).
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8.1.5 Associations between radiomic features and recurrence
In order to explore the prognostic value of imaging features in predicting
recurrence case/control for the validation set, we performed univariate logistic regression
on features found to be significant across the imaging phenotypes using the Significance
Analysis of Microarrays (SAM) algorithm198. SAM is a nonparametric statistical
algorithm designed to identify significant variables associated with a specific trait (e.g.
phenotype assignment). This exploratory analysis resulted in three imaging features,
histogram variance (AUC = 0.72), histogram uniformity (0.74), and morphologic
roundness (AUC= 0.70) demonstrating high discriminatory capacity for predicting case
from control in the 20 tumors, case/control matched for clinical and histopathological
covariates, in the validation cohort (Figure 8.4).
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Figure 8.4. Independent prognostic value of radiomic features from the validation cohort when predicting
recurrence case from matched controls. ROC curve for Histogram variance (A), ROC curve for histogram
uniformity (B), ROC curve for Morphologic roundness (C), and ROC curve for combined prediction using
variance, uniformity, and roundness (D).

8.2. Future directions: Feature harmonization
In order to explore the generalizability of radiomic features extracted from images
with varying voxel resolutions and from varying scanner modalities (e.g. manufacturer,
field strength), ComBat analysis may be subsequently employed to harmonize extracted
radiomic features. ComBat244,245 is a harmonization technique originally developed for
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genomic studies that aims to correct for variation in radiomic features due to image
parameter related batch effects using empirical Bayes to estimate location and scale
parameters to eliminate such variation. The impact of radiomic feature variation
introduced by image resolution and acquisition parameters such as field strength may be
mitigated using a nested ComBat246 approach. Future analysis for this work could
examine the potential effects of harmonized features when performing unsupervised
hierarchical clustering, and further explore the generalizability of harmonized features
when extending the imaging phenotypes to independent validation cohorts.

8.2 Future directions: Radiogenomic analysis
Radiogenomic analysis aims to leverage high-throughput genomic, molecular, and
sequencing data alongside high-throughput imaging data towards the advancement of
cancer precision care. In order to further understand the biological basis of imaging
phenotypes of tumor heterogeneity, one could explore potentially differential genomic
and proteomic expressions across imaging phenotypes to better understand the
physiologic mechanisms driving tumor image heterogeneity. This work196 has identified
associations between imaging phenotypes of spatial heterogeneity, which may capture
differential vascularization and angiogenic properties across the tumor lesion, and ER
percentage, cell differentiation, and mitotic stage. Future work may aim to further
illuminate more mechanistic properties of such spatial heterogeneity through
personalized genomic analyses. Additionally, the complementary information provided
by radiogenomic analyses may further improve prognostic performance when using an
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augmented model that integrates imaging biomarkers with established and emerging
molecular prognostic markers in stratifying women at higher risk of tumor recurrence, as
demonstrated in Chapter 4 of this work, thus allowing for improved personalization of
treatment strategies. Future work towards this aim may utilize a larger prospective trial in
which DCE-MRI images are acquired for woman diagnosed with locally advanced breast
cancer. Concurrently, FFPE primary tumor blocks may be analyzed for RNA extraction
and subsequent RNA-Seq data processing. Such analyses could allow for associations
between imaging phenotypes and biomarkers and intrinsic molecular biomarkers
including Claudin-low phenotypes, or PAM50 derived subgroups.

8.3 Future directions: Histopathologic spatial mapping
The validation of Rad-FIT clustering using simulated image phantoms allowed for
method development and validation, as well as demonstrated the added value of
incorporating spatial and temporal information for tumor voxel clustering as compared to
conventional methods utilizing spatial or temporal information, alone. Future work to
further understand the physiological differences in identified tumor sub-regions could
incorporate whole tissue histopathological analysis and leverage multi-modality spatial
registration to spatially align dynamic PET images with digital pathology images. Such
work could leverage the information afforded by histopathologic analysis to explore the
biological differences between Rad-FIT identified sub-regions and such longitudinal
analysis may provide insight into how the metabolic demands of tumor sub-populations
change in response to treatment. Furthermore, incorporation of spatially mappedhistopathologic images would allow for biological validation of imaging heterogeneity
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beyond that of biopsy derived histopathologic clinical covariates. This would have the
potential to explore whether spatially corresponding imaging and histopathologic
biomarkers capture similar physiology at varying resolutions or capture complementary
information. Lastly, such mapping could allow for insight into metabolic heterogeneity
within the tumor microenvironment as seen in FDG dynamic PET imaging.

8.4 Future directions: Multi-modality image analysis and deep learning
Medical imaging has the potential to be clinically leveraged as a non-invasive
assay during breast tumor diagnosis and treatment monitoring. Leveraging the differential
physiologic insights provided through modalities such as MRI and PET can allow for
whole-tumor analyses of targeted biology. Registering PET images to DCE-MR images
can localize regions of specific biological activation, as seen using targeted radiotracers
in PET, from which quantitative image features can be extracted from DCE-MR images.
This would provide an in vivo validation for heterogeneity features extracted from subregions within the tumor that may differ in underlying biology. Additionally, this
methodological development could be extended to understand the mechanisms of
additional types of cancer formation and development.
Work presented in this thesis largely focused on leveraging “hand-crafted”
features, either summarizing spatial heterogeneity through computer vision derived
features, or through features developed in order to summarize 4-D heterogeneity through
tumor sub-region analysis. Future work in exploring 4-D tumor heterogeneity could
leverage deep learning techniques in a myriad of ways. For example, autoencoders may
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be utilized to better summarize dynamic PET voxel time activity behavior by projecting
information non-linearly into a lower dimensional space, thereby providing additional
insight in identifying functionally discrete tumor sub-regions. Additionally, deep learning
visualization techniques, including deconvolutional networks247, may be used following a
model trained to predict recurrence free survival using longitudinal imaging, to provide
insight into more aggressive tumor regions driving recurrence and highlight what aspects
of tumor imaging properties are most predictive of this response. Such work may be used
to drive targeted radiation treatments with additional emphasis placed on these spatial
regions. Lastly, deep learning models could be utilized for non-linear combinations of
multi-modality imaging features or radiogenomic datasets for the development of
improved prognostic and predictive imaging biomarkers.
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Chapter 9 : Conclusions

Precision medicine aims to tailor disease prognosis and treatment based on
specific genotypic and phenotypic characteristics of an individual. Advances in
genomics, proteomics, and high-throughput sequencing have allowed for a personalized
understanding of breast tumor behaviors. Medical imaging is uniquely suited for
characterizing lesion heterogeneity through the ability to non-invasively image the entire
disease burden, and is routinely acquired throughout breast cancer care.
Characterizing intratumor heterogeneity may allow for personalized prognostic
and predictive biomarkers and provide complementary information to other precision
medicine assays, allowing for tailored patient treatment. Identifying imaging phenotypes
of tumor heterogeneity may allow for improved patient prognostic and predictive
stratification. Characterizing imaging representations of heterogeneous tumor sub-clones
may be used to select informative biopsy sites or direct treatment strategies. This work
demonstrates that computationally derived imaging biomarkers can provide non-invasive,
quantitative insight into breast tumor biology.
First, we identified imaging phenotypes of intratumor spatial heterogeneity in
DCE-MRI images of invasive breast cancer using radiomic analysis, as outlined in
Chapter 3. We reproduced and validated these imaging phenotypes in an independent,
publicly available cohort. We then evaluated the prognostic value of such imaging
phenotypes in predicting 10-year recurrence free survival (RFS), and found that tumors
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that had increased amounts of spatial heterogeneity prior to treatment or surgery, had an
increased likelihood of tumor recurrence. This may support the hypothesis that
heterogeneous tumors are associated with more aggressive tumor behavior and treatment
resistance. Furthermore, we found that high degrees of imaging heterogeneity were
associated with poorly defined tumors and tumors with higher mitotic grades, potentially
contributing to genetic diversity and sub-clonal evolution within these primary lesions.
Lastly, we determined that imaging phenotypes augmented prognostic models utilizing
conventional histopathologic biomarkers.
We then developed imaging biomarkers characterizing longitudinal changes in
spatial heterogeneity as presented in DCE-MRI images, as described in Chapter 4. Here
we calculated imaging features characterizing changes in the kinetic behaviors of primary
invasive breast lesions from baseline to an early-time point during the course of
neoadjuvant chemotherapy. These imaging features characterized heterogeneity induced
by a tumor’s change in vasculature or angiogenic properties in response to treatment. We
identified two intrinsic imaging phenotypes of such change in heterogeneity and
determined the prognostic value of these phenotypes when adding phenotype assignment
to established personalized molecular signatures. Interpretation of the two radiomic
phenotypes as capturing an increase and decrease in intratumor heterogeneity from pretreatment to early-treatment showed that tumors assigned to the phenotype with
increasing intratumor heterogeneity had a greater number of future recurrences.
Additionally, with the stratification of women within functional tumor volume (FTV), a
previously described and broadly established imaging prognostic biomarker, subgroups
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by phenotype demonstrated the added value of radiomic analysis of change in intratumor
heterogeneity in modeling prognosis. We illuminated that augmenting clinical,
histopathologic, and molecular covariates with imaging phenotypes may allow for
personalized risk stratification and early adaptation of treatment strategies.
Together, this work demonstrates novel phenotypic differences in clinical imaging
representations of primary breast tumors at diagnosis as well as phenotypic differences in
how tumor imaging presentations of heterogeneity change in response to treatment. This
work also explored prognostic and predictive clinical imaging biomarkers to character
this heterogeneity. These imaging biomarkers captured spatial and temporal
heterogeneity through dynamic clinical imaging modalities using baseline diagnostic
clinical imaging and also explored longitudinal changes in tumor heterogeneity in
response to neoadjuvant treatment.
We then further aimed to characterize spatial and temporal heterogeneity in
primary breast lesions by identifying intratumor regions of varying functional behaviors.
We leveraged the improved dynamic image sampling afforded through dynamic PET
imaging to understand the potentially differential kinetic patterns across a single tumor
following contrast tracer injection. To do so, we developed a tracer agnostic segmentation
algorithm, Radiomic Functional Intratumor (Rad-FIT) clustering, that identifies spatially
constrained, functionally discrete sub-regions. This algorithm can be applied to non-rigid,
arbitrarily shaped regions without manual initialization or defined control points.
Development and validation of this segmentation algorithm in Chapter 5 demonstrated
improved performance over established unsupervised clustering algorithms when
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segmenting simulated image phantoms. The results from these experiments showed that a
segmentation algorithm incorporating both spatial and temporal information had
improved 4-D segmentation accuracy over established methods using only temporal
dynamics or spatial information, alone.
Using this developed 4-D segmentation algorithm, we identified three sub-regions
within locally advanced breast lesions imaged with dynamic FDG-PET in a retrospective
analysis. In order to summarize the metabolic heterogeneity within each tumor by
characterizing the three sub-regions, we developed a functional tumor heterogeneity
(FTH) imaging signature describing how compact and separate the detected sub-regions
were. We found that quantifying intratumor metabolic heterogeneity using this FTH
imaging signature augmented established histopathologic covariates in Cox-regression
models predicting RFS. This work, outlined in Chapter 6, suggested that imaging
characteristics of 4-D metabolic functional heterogeneity may be leveraged as a
prognostic biomarker by providing information not previously identified by ROI-based
kinetic analyses.
In Chapter 7 we explored extending Rad-FIT clustering to be completely
unsupervised, or Unsupervised Rad-FIT (U-Rad-FIT) clustering. We explored methods to
determine the optimal number of spatially constrained functionally discrete sub-regions
within a single lesion towards developing precision medicine-based imaging biomarkers.
We evaluated algorithm performance using novel dynamic imaging phantoms simulating
a heterogeneous lesion.
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Lastly, we explored the extension of the techniques and imaging biomarkers
developed throughout this thesis to images of pre-cancerous breast lesions and discussed
future directions and ongoing experiments for the continued development and validation
of imaging biomarkers of intratumor heterogeneity.
This thesis provides evidence that imaging biomarkers have the potential to be
utilized towards precision medicine for cancer care. While this work focused on breast
cancer, future work should also seek to evaluate the developed approaches to other cancer
sites. Further developments in the standardization, interpretation, and validation of such
biomarkers are required for ultimately translating quantitative imaging biomarkers from
development in a research setting to implementations in oncologic clinical practice.
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Appendix A: Radiomic features
Table A.1. Gray-level histogram texture features
Gray-level
histogram
features

Qualitative description

Mean

Mean gray-level value

Min

Min gray-level value

Min(k)

Max

Max gray-level value

Max(k)

5th
Percentile

Histogram bin that 5% of k: 5% of values ≤ k
grey level values are less
than or equal to

Mean 5th

Mean value of gray-level
values that 5% of grey
level values are less than
or equal to

95th
Percentile

Histogram bin that 95%
of grey level values are
greater than or equal to

Mean 95th

Mean value of gray-level
values that 95% of grey
level values are greater
than or equal to

Sum

Sum of gray-level values

Sigma

Measure of variation of
gray-level values around
the mean

Entropy

Measure of histogram
nonuniformity

Kurtosis

Measure
flatness

of

histogram

Skewness

Measure of
symmetry

histogram

Mathematical description

for k ≤ fifth percentile

k: 95% of values ≥ k

for k ≥ ninety- fifth percentile
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Table A.2. Representative gray-level co-occurrence matrix texture features
Co-occurrence
matrix features

Qualitative description

Contrast

Intensity contrast between
pixel and its neighbor

Correlation

Linear gray-level dependence

Homogeneity

Closeness of distribution in
co-occurrence matrix to
matrix diagonal

Energy

Certainty of gray-level cooccurrence

Entropy

Uncertainty of gray-level cooccurrence

Inverse Difference
Moment (IDM)

Local homogeneity in graylevel co-occurrence

Cluster Shade

Asymmetry in gray-level
values
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Mathematical description

Table A.3. Run-length texture features
Run-length
features
Short run
emphasis (SRE)

Emphasis on short runs

(Long run
emphasis (LRE)

Emphasis on long runs

Gray level
nonuniformity
(GLN)

Degree of gray-level run
dissimilarity

Run length
nonuniformity
(RLN)

Dissimilarity in length of runs

Run percentage
(RP)

Distribution of runs

Low gray level
run emphasis
(LGRE)

Emphasis on low gray-level
values

High gray level
run emphasis
(HGRE)

Emphasis on high-gray-level
values

Short run low
gray level
emphasis
(SRLGE)

Emphasis on short runs with
low-gray-level values

Short run high
gray level
emphasis
(SRHGE)

Emphasis on short runs with
high-gray-level values

nr is the total number of runs, R(i,j) represents the number of runs with pixels of gray-level
intensity value, i, and length of run, j. 128 gray-levels were used. Estimated by averaging over 0°,
45°, 90°, and 135° orientations.
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Table A.4. Structural texture features

Structural feature

Qualitative
description

Local Binary Pattern (LBP)

Intensity variation
between a pixel and its
neighboring pixels.

Mathematical description

Ic and Ip are gray-level intensity values for pixel (xc,yc) and pixel (xp,yp). q= indicator
function, 0 for negative inputs and 1 for non-negative inputs.Q, P= parameters to set pixel
neighborhood size, set to 1 and 8, respectively39,40.
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Appendix B: Personalized molecular signatures
Table B.1. Recreated MammaPrint classification results compared to the original
Esserman et al. classification results.
Low risk

High risk

Esserman’s overall results

11

109

Recreated overall results

10

108

Esserman’s PCR (positive) results

0/11

25/105

Recreated PCR (positive) results

2/10

26/108

Esserman’s RCB (0 or I class)
results

1/9

31/99

Recreated RCB (0 or I class)
results

2/10

36/108

Table B.2. Recreated p53 mutation gene signature classification results compared to the
original Esserman et al. classification results.
p53 wildtype

p53 mutant

Esserman’s overall results

59

61

Recreated overall results

57

61

Esserman’s PCR (positive) results

5/58

20/58

Recreated PCR (positive) results

8/57

20/61

Esserman’s RCB (0 or I class)
results

10/53

22/55

Recreated RCB (0 or I class)
results

15/57

23/61
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Table B.3. Recreated PAM50 ROR-S gene signature classification results compared to
the original Esserman et al. classification results.
Low risk

Intermediate
risk

High risk

Esserman’s overall results

32

42

46

Recreated overall results

31

41

46

Esserman’s PCR
(positive) results

2/32

7/40

16/44

Recreated PCR (positive)
results

3/31

11/41

14/46

Esserman’s RCB (0 or I
class) results

5/28

9/38

18/42

Recreated RCB (0 or I
class) results

6/31

14/41

18/46

B.1. Molecular signatures
Gene expression data were obtained from Gene Expression Omnibus (GEO)185,186 using
the publicly available samples from the Esserman et al. study (accession GSE22226)187
that match the ACRIN 6657/I-SPY 1 MRI data of the discovery cohort TCIA dataset.
Samples have been analyzed using two microarray platforms and can be found in GEO
under accessions GPL1708 (n = 130) and GPL4133 (n = 20). Initially, gene signature sets
were validated by recreating the Esserman et. al study. Afterwards, the final gene
signatures set were used solely and in combination with the MRI information of patients
to assess their classifying value.
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Recreation of Esserman et al. study
Samples were filtered as in Esserman et al.187 down to n = 120 (initially 121, but one
entry was removed due to incomplete data). Briefly, only patients with both microarray
expression data and HR/HER2 status, RCB and negative trastuzumab treatment status
were kept in the final set. Trastuzumab status was taken directly from the GEO
phenotype information, while RCB class and HR/HER2 status were extracted using the
Clinical and Outcome Data found at:
https://wiki.cancerimagingarchive.net/display/Public/ISPY1.

Minimal

differences

in

clinical data may be explained due to different updates in the various data sources, as the
ACRIN 6657/I-SPY 1 clinical trial was an extended, long-term prospective study.
Microarray intensity values provided in GSE22226 are expressed as

Lowess-

normalized mean ratio values.
Molecular profiling was built using three of the four gene signatures that are mentioned
in Esserman et al. study i.e. 70-gene signature (MammaPrint)190,191, p53 mutation
signature194 and PAM50 risk of recurrence (ROR-S)192,193. The wound-healing response
gene signature248 recreation proved to be unsuccessful due to unavailability of the
original supplementary data and microarray probes that comprise the signature gene set.
Annotation of the probes was extracted automatically from the latest GEO platform
annotation found in the NCBI GEO repository.
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B.2. MammaPrint
The original experiment consisted of 98 primary breast cancer human samples, of which
78 were metastasis-free. 44/78 were recurrence-free for more than 5 years, constituting
the “good prognosis group”. In short, the authors performed hierarchical clustering using
significantly regulated genes (two-fold change, p < 0.01), Pearson correlation coefficient
calculation between the prognostic category and the log expression ratio across all
samples and Monte Carlo randomization of the association between the expression ratio
and prognosis category to discern the best candidate genes (n = 231) to predict
recurrence-free survival (RFS). After leave-one-out cross validation for different subsets
of genes, the authors ended up with the 70-gene signature.
Classification is achieved by calculating the cosine similarity between the MammaPrint
gene signature expression values of the sample to be classified and the average of the
MammaPrint gene signature expression values of the “good prognosis group” in the
original study. A value greater than -0.4 (threshold suggested by the MammaPrint
authors) is considered to classify the sample as “high risk” with respect to future
recurrence191.
The MammaPrint 70-gene signature consists of 70 microarray probes. Original analysis
was performed using 25K human oligonucleotide two-color microarrays developed by
Rosetta. The 70 probes correspond to 56 genes and 14 Expressed Sequence Tags (ESTs).
Expression values provided in supplementary data are calculated as
with median background intensity subtraction. Specifically:

172

mean ratio

In our study, the cosine similarities were calculated using the genefu R package249. Probe
matching between Esserman et al. microarray annotation and MammaPrint was done
using Entrez IDs, resulting into a shrinkage of the probes number (52/70). A possible
explanation for this is due to updated annotation information related to the genes
overlapping those probes. Furthermore, in order to make the two platform intensities
comparable, the Esserman et al. expression values were recalculated to match the
MammaPrint values.

and NA values (introduced due to background subtraction)

were converted to 0 prior to cosine similarity estimation.

B.3. p53 mutation signature
The p53 mutation gene signature consists of 52 microarray probes derived from the
unsupervised clustering of datasets with known p53 mutation status, which is used to
classify samples’ status as p53 wildtype or p53 mutant. Tumor suppressor p53 mutations
are found more frequently in aggressive breast cancers. In the original study, a SAM250
derived gene list along with a false discovery rate of less than 5% was given as input to
an average linkage hierarchical cluster analysis. The analysis was conducted using
Pearson correlation in the Cluster program. This gene list was then refined by comparing
the p53-associated gene lists between tumor samples and cell lines, leading to a robust
list of 52 genes that were common to both data sets (in vitro and in vivo).
According to Troester et al.194, classification was performed by calculating the
Spearman’s correlation metric between the samples under examination and the training
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set centroids, similar to the MammaPrint method. Centroids are represented as vectors of
the mean average of each gene expression in the p53 signature, one per p53 status group
(wildtype vs. mutant). Greater correlation to one of the centroids classifies the sample as
such.
The training dataset used to create the centroids consists of 66 microarray samples from
Sorlie et al.

251

(2001), which are deposited in GEO under accession GSE3193. In the

experiment, 4 different microarray platforms were used i.e. GPL180, GPL2776,
GPL2777, GPL2778. Microarray platform/source systematic biases between them were
originally corrected using the Distance Weighted Discrimination (DWD) algorithm. Due
to lack of an R package that implements DWD, in our study we used the ComBat
function found in the SVA R package252, which utilizes an Empirical Bayes approach.
Three groups were designated for batch removal (A: Sorlie et al. (2001) data, B:
Esserman’s GPL1708 data, C: Esserman’s GPL4133 data). Non-finite values were
ignored.
47/52 probes were common in all datasets by matching their Entrez IDs, which
comprised the final p53 gene signature used for the recreation analysis. The same
rationale as in the MammaPrint section applies here:

and

mean ratio and

median background intensity subtraction were used in the different Sorlie et al. (2001)
microarray datasets, thus every raw intensity was transformed into
values, including the microarray intensity values from Esserman et al..
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mean ratio

B.4. PAM50 ROR-S
Risk of recurrence score is used to classify patients into three categories (low, medium
and high risk of relapse) according to an estimated risk value, using predefined
thresholds. The original study progressively identified a 50-gene set through hierarchical
clustering and the single sample predictor algorithm (SSP), which was used to cluster 189
breast cancer and 29 normal samples into 5 intrinsic subtypes (Luminal A, Luminal B,
HER2-enriched, Basal-like and Normal-like) by employing the Prediction Analysis of
Microarray (PAM) centroid-based clustering algorithm. Distance to each subtype was
calculated using Spearman’s rank correlation, representing the proximity of each sample
to each category. Then, the authors performed univariate and multivariate analyses to
determine the significance of those subtypes and trained a multivariable Cox model using
the Ridge regression fit to the node-negative, untreated subset of the van de Vijver
cohort253. In order to classify a sample into one of the risk categories, one needs to
calculate the resulting weighted sum of the intrinsic subtype Spearman’s rank coefficients
using the following equation:

We utilized the genefu R package (rorS function) to classify our samples. Probe matching
between the two gene sets was successfully done using Entrez IDs, which resulted in a
complete 50/50 annotation. As in MammaPrint, the two platforms’ intensities were
incomparable. Thus, the Esserman et al. intensities were recalculated with no background
subtraction and no Lowess normalization and expressed using log2 mean ratios.
Predefined ROR-S thresholds were used i.e. low
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29, 29

moderate

53, high ≥ 53.
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